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1 Summary 
 
Kaposi’s Sarcoma Associated Herpesvirus (KSHV) or Human Herpesvirus-8 (HHV-8) 
is the most recently identified human -2 herpesvirus and has been implicated in 
Kaposi’s Sarcoma (KS) and primary effusion lymphoma (PEL). At the right end of the 
genome KSHV encodes the complex kaposin locus, which consists of two distinct 
sets of 23 amino acid direct repeats, DR2 and DR1, followed by a short domain 
originally referred to as open reading frame (ORF) K12. Translational initiation at 
multiple alternative CUG and one AUG start codons causes expression of a gradient 
of kaposin molecules with varying length and targeting motifs from one single 
transcript.  
The aim of the present study was to investigate in detail the expression pattern of the 
kaposin locus and the cellular localization and function of kaposin protein isoforms 
expressed in the KSHV+ PEL cell line BCBL-1. The multitude of translational 
products from all three reading frames could be resolved and different isoforms 
assigned to distinct cellular compartments. Depending on the alternative start codon 
used, the DR1 repeats representing a functional effector domain are fused either to 
the DR2 repeats harboring a nuclear localization sequence (NLS), or to K12, which 
encodes a transmembrane domain. Expression of kaposin in the nucleus (kaposin B) 
causes an activation of the AP-1 transcription factor and cellular promoters. The 
observed AP-1 induction is dependent on nuclear localization of both DR2 and DR1 
repeats, since substitution of DR2 with a SV-40 NLS was not sufficient to restore 
activation. Other kaposin isoforms which are found in the cytosol (kaposin E) or 
membrane-associated (kaposin D) failed to activate AP-1. If co-expressed, however, 
kaposin D and E were able to modulate the kaposin B-caused induction, presumably 
mediated by a direct interaction between DR2 and DR1. 
The results presented in this study indicate a novel autoregulatory mechanism based 
on bidirectional targeting of a viral protein to distinct subcellular compartments by 
expression from different start codons and reading frames. Supported by the 
complexity of the translational program and the conservation of the repeat regions, 
these findings imply that kaposin isoforms have important functions in the viral life 
cycle. 
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2 Introduction 
 
2.1 Herpesviruses 
 
The family of Herpesviridae encompasses more than 100 different species in animals 
and human. A typical herpesvirus virion consists of four structural components. In the 
center a core range is located, which contains the linear double stranded DNA. This 
core range is encased by an 100 to 110 nm spanning icosahedral capsid, which 
consists of 12 pentameric and 150 hexameric capsomers. Both, core and capsid 
together form the so-called nucleocapsid. The capsid is surrounded by an 
amorphous substance, the tegument, which consists of electron-dense material and 
can vary in its density; it is most probably responsible for the varying diameter of the 
different herpes virions (from 120 nm to nearly 300 nm). Tegument and nucleocapsid 
are enclosed by a membrane of cellular origin (envelope) containing virally encoded 
glycoproteins (spikes) (Fig. 1).  
The genomes of herpesviruses differ both in size and in GC-content. The GC-content 
varies between 32% in canine herpesvirus and 75% in herpesvirus simiae. Varicella 
Zoster Virus (VZV) possesses among the so far described herpesviruses with 
approximately 125 kbp the smallest, the humane and the murine cytomegalovirus 
(HCMV and MCMV, respectively) with approximately 230 kbp the largest genome(s) 
with a coding capacity for approximately 200 proteins (Chee et al., 1990; Rawlinson 
et al., 1996) .  
Although the length of the DNA is specific for each herpesvirus, the differences in 
genome size can vary up to 10 kbp within independent isolates of a virus species, 
which reflects usually a different number of terminal or internal repetitive sequences. 
A further peculiarity of all herpesviruses is the presence of virus-specific enzymes 
and other factors, which are involved in the nucleic acid synthesis (e.g. DNA 
polymerase, helicase, primase) and in the DNA metabolism (e.g. thymidine kinase, 
dUTPase). In addition, all herpesviruses encode at least one protease and a differing 
number of protein kinases. 
Viral DNA synthesis and the assembly of the capsids take place in the nucleus of the 
host cell. During exit of the nucleus through the nuclear membrane capsids become 
enveloped. With some herpesviruses this first envelope is removed and replaced by 
a new membrane from cytoplasmatic organelles. A further typical characteristic of 
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herpesviruses is the irreversible destruction of the host cell during the production and 
release of infectious virus progeny. However, the probably most important and 
characteristic feature of all herpesvirus species is the ability to switch after an often 
asymptomatic primary infection into a state of latency and to persist life-long in the 
host. In latently infected cells, the virus genome is present extra-chromosomally and 
only few viral genes are expressed. Thus, during latency no infectious virions can be 
isolated from infected tissue. Due to endogenous and exogenous factors (e.g. stress, 
immunosuppression, UV-light, hormones etc.) the herpesvirus can reactivate and 
disease symptoms reoccur. The family of the Herpesviridae can be divided into the 
three Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae subfamilies. 
The -herpesviruses are characterized by the fact that they exhibit a broad host 
range and a short replication cycle. The infection spreads in cell culture fast and 
leads to an efficient destruction of infected cells. -herpesviruses establish latent 
infections in sensory ganglia. Important representatives of human pathogenic -
herpesviruses are the Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2), 
which cause blisters in the lip and genital region, and the Varicella Zoster Virus 
(VZV), the causative agent of varicella (chickenpox) and Zoster (shingles). Contrary 
to the -herpesviruses, the β-herpesviruses show a pronounced host specificity, a 
long reproduction cycle and a slow propagation in cell culture. The size of infected 
cells is frequently increased (cytomegalic), which was taken in account in the naming 
of some β-herpesviruses (e.g. HCMV, MCMV). β-herpesviruses can establish latency 
in different cells and tissues. The -herpesviruses are characterised by a restricted 
host specificity. Usually their host range is limited to the family from which their 
natural host originates. In vitro, all -herpesviruses replicate in lymphoblastoid cells 
and some also cause lytic infections in epitheloid cells and fibroblasts. This 
herpesvirus subfamily has a selectivity for either T or B lymphocytes, in which latent 
virus preferentially can be detected. The most well-known human representative is 
the B-cell-specific Epstein-Barr Virus (EBV), which is the causative agent of 
infectious mononucleosis (“kissing disease”). EBV is an oncogenic virus and 
associated with two endemic tumors, Burkitt’s lymphoma and nasopharyngeal 
carcinoma, as well as with Hodgkin’s disease. KSHV, another representative of the -
herpesvirus subfamily is also associated with several tumor entities, similar to EBV 
(Chee et al., 1990; Roizman, 1996). 
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Fig. 1: The herpesvirus particle 
Schematic model of a herpesvirus particle (adapted from Reschke, 1994). Major virion components 
are indicated. 
 
 
2.2 Replication cycle of herpesviruses 
 
The infection of a cell begins with the specific binding of virus envelope proteins to 
receptor molecules on the surface of the host cell. After adsorption of the virions the 
viral envelope fuses with the cell membrane and the nucleocapsid is released into 
the cytoplasm. The uncovered virus genome is circulized and transported into the 
nucleus, where transcription and replication take place. The replicated virus DNA is 
packed into capsids, which receive their first envelope by budding at the inner 
nuclear membrane. Depending on the herpesvirus species the first envelope 
membrane is replaced in the Golgi or ER and the virus progeny is released by 
budding.  
Gene expression in herpesviruses is cascade-like regulated and can be divided in 
three distinct phases: immediate early (IE), early (E) and late (L) (Honess and 
Roizman, 1974). The immediate early phase begins immediately after the infection. 
For the transcription of the IE genes no de novo synthesis of viral proteins is 
necessary. IE proteins possess predominantly regulatory functions, and at least one 
nucleocapsid
tegument
envelope
glycoproteins
genome
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IE protein is necessary for the initiation of the early phase (Honess and Roizman, 
1975). The activation of the early genes takes place primarily on the transcriptional 
level (Godowski and Knipe, 1986). During the early phase proteins are produced 
which are necessary for replication of the viral genome (e.g. viral DNA polymerase). 
The start of DNA replication defines the beginning of the late phase. In the late phase 
mainly structural proteins necessary for the formation of the virions are synthesized. 
 
 
2.3 Kaposi’s Sarcoma (KS)-Associated Herpesvirus (KSHV) 
 
2.3.1 Disease association 
 
The Hungarian dermatologist Moritz Kaposi working in Vienna was the first who 
described Kaposi’s Sarcoma in 1872. He published a case report of five men with 
“idiopathic multiple pigmented sarcoma of the skin” including a patient who 
developed visceral disease in the lung and gastrointestinal tract (Antman, 2000). Two 
decades later this idiopathic multiple pigmented sarcoma of the skin was termed KS 
according to the proposal of another prominent dermatologist, Kobner, and is now 
referred to as classic KS. In central Africa endemic KS is one of the most frequent 
tumors whereas in North America and Northern Europe KS appeared rarely before 
the acquired immunodeficiency syndrome (AIDS) epidemic. However, the AIDS 
epidemic made KS to the most common AIDS-associated cancer and thus it 
contributes considerably to morbidity and mortality in AIDS patients (Ahmed et al., 
2001). In addition, HIV seronegative, homosexual men have a higher risk for 
developing KS in comparison to individuals in countries where the rates of KS are 
higher (Ganem, 1997). KS is one of the most frequent post-transplant neoplasms 
predominantly after kidney transplantation. These post-transplant KS tumors regress 
when immunosuppressive therapy is stopped, suggesting the importance of the host 
immune system (Penn, 1978). KSHV is the most recently discovered human -
herpesvirus and shows tropism primarily for endothelial cells and B-lymphocytes, but 
can also infect other cell types with limited efficiency. It is the eighth human 
herpesvirus isolated to date and is therefore also named Human Herpesvirus 8 
(HHV-8)  (Antman, 2000; Chang et al., 1994). KSHV was initially isolated from KS 
tissue but was later also found to be associated with pleural effusion lymphomas 
(PEL [body cavity-based lymphomas (BCBL)]) (Chang et al., 1994). 
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Although other pathogenic agents (among others CMV, HIV-1 and mycoplasm) were 
isolated from Kaposi’s Sarcoma, a preponderance of data strongly suggests that 
KSHV is the etiologic agent of KS and may also be a critical player in the 
development of other lymphoproliferative disorders such as PEL and multicentric 
Castleman’s disease (MCD) (Arvanitakis et al., 1996; Beral et al., 1990; Boshoff et 
al., 1995; Renne et al., 1996b; Siegal et al., 1990). Most PEL are positive for KSHV 
and EBV (80-90%), which is reflected by the occurrence of both viruses in cell lines 
derived from this tumor.  
 
 
2.3.1.1 Kaposi’s Sarcoma (KS) 
 
Kaposi’s Sarcoma is clinically most relevant among the KSHV associated tumors. It 
is an unusual neoplasm characterized by multifocal dark brown or purple lesions and 
differs from most other tumors by several characteristic features (Fig. 2). In KS, the 
lesions contain multiple cell types, of which the endothelial derived spindle cells are 
predominant (Boshoff et al., 1997). The clonality of KS is controversely discussed 
(Judde et al., 2000; Gill et al., 1998; Rabkin et al., 1997). Additionally, the KS lesions 
are characterized by the infiltration of inflammatory leukocytes as well as a profusion 
of neovascular elements (Monini et al., 1999). In immunocompetent patients KS is a 
slow growing tumor with low malignant potential (Ganem, 1997). In 
immunocompromised individuals, KS is more aggressive and can be letal. In cases 
where the immune competence was restored, complete remission of the disease 
state was observed, which is quite different from other aggressive tumors (Boshoff et 
al., 1997; Fiorelli et al., 1998). The presence of KSHV in PEL has been documented 
and coinfection with EBV was shown for the majority of cloned cell lines, including 
BC-1 and BC-2 (Cesarman et al., 1996). However, several PEL cell lines including 
BC-3 and BCBL1 were described, which showed no detectable levels of EBV 
(Arvanitakis et al., 1997; Renne et al., 1996b). Although B-cell markers are 
completely down-regulated, the clonal immunoglobulin heavy chain rearrangement 
indicated that these cells are of B-cell origin. KSHV is able to infect human B-cell 
lines and may be involved in the pathogenesis of PEL in HIV-positive AIDS patients. 
KSHV is also able to infect and replicate in other cell lines, but considerably less 
efficiently than seen in the PEL cell lines (Cerimele et al., 2001; Foreman et al., 
1997). Four distinct clinical variants of KS can be distinguished. Classic KS is a 
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severly growing, little aggressive tumor, which typically affects elderly men of 
Mediterranean and eastern European origin and is mostly indolent; endemic KS, 
which is frequent in equatorial, eastern and southern Africa and is a clinically more 
aggressive form than classic KS (Wabinga et al., 1993); post-transplant or iatrogenic 
KS, which develops in patients undergoing immunosuppressive therapy to prevent 
graft rejection after organ transplantation (Regamey et al., 1998) and finally, AIDS-
associated KS, the most aggressive form of the disease, is most frequently seen in 
gay and bisexual men, indicating that transmission is likely through high risk sexual 
practices (Gao et al., 1996). 
 
 
 
Fig. 2: Cutaneous forms of a Kaposis’s Sarcoma 
(A) Kaposi’s Sarcoma of the lower leg and foot. Lesion at the lower leg are plaque-like, brown and 
sharply defined. Confluent Lesions at the foot exhibit firm purple nodes (B) AIDS-related Kaposi’s 
Sarcoma of a 29 year-old man. Lesions are multifocal distributed in form of dark purple nodes 
(pictures online published in the Dermatology Online Atlas [http://www.dermis.net/doia/] according 
to Diepgen and Eysenbach, 1998). 
 
 
2.3.1.2 Primary effusion lymphoma (PEL) 
 
PEL (previously termed BCBL), is a rare, rapidly fatal, non-Hodgkin’s malignancy 
associated with KSHV infection. In general, it is present as a pleural or pericardial 
effusion without a detectable mass or peripheral lymphoadenopathy (Arvanitakis et 
al., 1996). Additionally, PEL can also manifest as a solid mass in the lymph nodes, 
lungs or the gastrointestinal tract. PEL is found mainly in HIV seropositive individuals 
in advanced stages of immunosuppression, but also in HIV seronegative patients. 
Although EBV negative and KSHV positive PEL have been described, PEL cells are 
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frequently co-infected with both viruses. Southern blot analysis revealed that the 
copy number of KSHV genomes in PEL cells is maintained at 50-150 copies per cell, 
which is substantially more than the numbers observed in KSHV-infected spindle 
cells. 
 
 
2.3.1.3 Multicentric Castleman’s disease (MCD) 
 
The multicentric Castleman’s disease belongs to the atypic- or  pseudo-lymphoma 
and is thought to be mediated by interleukin (IL)-6 overexpression (Ablashi et al., 
2002). The correlation between KSHV viral load and the course of the disease 
suggests a functional role of KSHV in MCD (Grandadam et al., 1997). 
The virus is detected in most HIV-seropositive cases of MCD as well as in 
approximately 40% of HIV-seronegative MCD cases. The KSHV positive MCD cases 
are now understood as a distinct subset of MCD, termed plasmablastic MCD, which 
are characterized by the occurrence of large plasmablastic cells harbouring KSHV 
(Dupin et al., 2000). Unlike PEL cells, co-infection by EBV has not been detected in 
MCD plasmablasts. The rate of lytically infected tumor cells is considerably higher in 
MCD in comparison to KS and PEL, suggesting a different role of KSHV in 
pathogenesis (Cathomas, 2000). 
 
 
2.3.2 The KSHV particle 
 
KSHV shows a typical herpesvirus morphology: virus particles have a diameter of 
100- to 150-nm with a lipid envelope and an electron-dense central core (Renne et 
al., 1996a). The icosahedral capsid consists of 162 hexagonal capsomeres and is 
approximately 125 nm (1250 Å) in diameter (Wu et al., 2000). Three types of capsids, 
named A, B and C, are released from PEL cells after TPA and sodium butyrate 
treatment (Fig. 3). Fully mature C-capsids contain, in declining order of abundance, 
the polypeptides ORF25/MCP (major capsid protein), ORF65/SCIP (small capsomer-
interacting protein), ORF26/TRI-2 (triplex-2), ORF62/TRI-1 and the 160- to 170-kb 
viral genome. They have a total mass of approximately 300 megadaltons. A and B 
capsids are constructed similarly but lack viral DNA. In addition, the B capsids 
contain the scaffolding protein encoded by ORF17.5 (Nealon et al., 2001). Mature 
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virions carry a glycoprotein coat and between the capsid and the envelope a protein-
filled region, the tegument is located. The central core is torus-shaped, 75-nm in size 
and composed of DNA and protein. In appearance, KSHV is not distinguishable from 
-, β-, and other -herpesvirus particles (International Agency for Research on 
Cancer, 1997). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3: Electron cryomicroscopy of HHV-8 capsids 
(A) Empty A-capsids, one B-capsid (black arrow) and one DNA containing C-capsid (white arrow).(B) 
Enlarged view of an intermediate B capsid, which contains scaffolding protein. Characteristic 
hexagonal pattern of the capsomeres (e.g. arrow) is indicated. (C) Fully mature C-capsid with 
characteristic striated fingerprint-like pattern (adapted from Wu et al., 2000).  
 
 
2.3.3 The KSHV genome 
 
KSHV is a member of the 2-subgroup of the -herpesvirus family, rhadinovirus 
genera, which share a collinear genomic organization with each other. The coding 
capacity of the KSHV genome was determined by sequencing viral DNA of a PEL 
cell line as well as of KS biopsy specimens, both revealing the characteristic synteny 
of rhadinoviruses (Russo et al., 1996; Neipel et al., 1997). Supplementing this 
approach, Gardella gel analyses were performed to specify the size and 
conformation of the viral nucleic acid (Renne et al., 1996a). During latency, the KSHV 
genome of PEL cell lines is maintained as a circular, multicopy episome (similar to 
the Herpesvirus saimiri [HVS] and EBV genomes) and includes multiple GC-rich, 
A B
C
1000 Å
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801-bp terminal repeats enclosing approximately 145 kb of “unique” sequence 
(Lagunoff and Ganem, 1997; Moore and Chang, 2001). During the lytic replication 
cycle, viral progeny DNA is ultimately synthesized as linear, single-unit genomes 
destined for packaging into mature virions (Renne et al., 1996a).  
KSHV harbors at least 89 ORFs. A comparison between KSHV and HVS (the 
prototype 2-herpesvirus) reveals a strikingly similar genetic arrangement (Neipel et 
al., 1997; Russo et al., 1996). Both viruses share 68 conserved genes that are 
arranged collinearly, interrupted by interspersed regions of genes unique to each 
virus. All genes were numbered consecutively from the left to the right side of the 
genome. The conserved genes have been marked by the prefix “ORF” and the 
unique genes were designated K1 to K15 (Fig. 4) (Russo et al., 1996). More recently, 
the publication of the complete DNA sequences of the murine gammaherpesvirus 68 
and several primate rhadinoviruses confirmed the conservation of this genetic 
organization and expanded it to non-human members of the 2-herpesviruses family 
(Alexander et al., 2000; Searles et al., 1999; Virgin et al., 1997). Those genes which 
display the highest degree of conservation among these viruses are predicted to 
have metabolic and catalytic functions in replication of the viral DNA or contribute to 
the virion structure and are taken together in a set of “ancient” genes conserved in all 
mammalian herpesviruses (McGeoch and Davison, 1999; Simas and Efstathiou, 
1998). In KSHV, these include the DNA polymerase and the processivity factor 
(ORF9 and ORF59, respectively), the DNA helicase-primase (ORF40, ORF41, and 
ORF44), the thymidylate synthase (ORF70), and the thymidine kinase (ORF21). 
Characteristically, KSHV as well as other -herpesviruses harbor a large number of 
ORFs which share homology to known cellular genes and are postulated being 
pirated from host chromosomes during viral evolution. Some of these genes 
participate in the down-modulation of the immune response, circumvent cellular 
systems of targeting infected cells or are involved in cell growth, differentiation and 
nucleotide biosynthesis. They include the Bcl-2, IL-8R, and MIP-IK, vIL-6, DHFR and 
the D-type viral cyclin, whose functions are usually distinct to that of their cellular 
homologs (Alexander et al., 2000; Russo et al., 1996). The KSHV genome also 
contains two lytic origins of DNA replication, that are inverted duplications of each 
other: the left is located between K4.2 and K5, and the right between K12 and 
ORF71 (AuCoin et al., 2002; Lin et al., 2003). 
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These genomic analyses identified the viral DNA polymerase gene as the gene with 
the highest intervirus identity, facilitating the construction of rhadinoviral phylogenetic 
trees which include KSHV, HVS, and the primate rhadinoviruses that have been 
identified over the last half decade (Fig. 5). The group of rhadinoviruses has since 
been subdivided into those of New World and Old World primates (Greensill et al., 
2000b). Probably the most closest relative of KSHV is the Pan troglodytes 
(chimpanzee) rhadinovirus 1 (PtRV-1), which encodes a DNA polymerase gene that 
has 93.2% amino acid identity to the KSHV polymerase (Greensill et al., 2000a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Phylogenetic trees 
(A) Rhadinoviruses divide into a New World- and an Old World-subgroup. DNA maximum likelihood 
tree for herpesviruses (Greensill et al., 2000b). (B) Pan troglodytes rhadinovirus 1 is the closest 
relative to KSHV found so far. Neighbour-joining protein distance tree of different rhadinoviruses 
(Greensill et al., 2000a). 
Abbreviations: HSV, Herpes simplex virus; VZV, Varicella zoster virus; HHV, Human herpes virus; 
HCMV, Human cytomegalovirus; EBV, Epstein-Barr virus; HVA, Herpesvirus ateles; HVS, Herpesvirus 
saimiri; RRV, Rhesus rhadinovirus; CHRV-1,2, Chlorocebus rhadinovirus 1 and 2; RFHVMm, Mn, 
Retroperitoneal fibromatosis herpesvirus of rhesus and pigtailed macaques; MneRV-2, rhesus and 
pigtailed macaque rhadinovirus; PtRV-1, Pan troglodytes rhadinovirus 1. Numbers refer to the 
percentage of repeated analyses that gave the same tree topology (“bootstrap” values). 
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2.3.4 Latent and lytic gene expression in KSHV 
 
As all herpesviruses, KSHV is able to infect cells latently (non-productive) and 
lytically (productive). This biphasic life cycle is characterized by a distinct gene 
expression program in each case and was recognized early in both KS lesions and 
cultured PEL specimens (Miller et al., 1996; Miller et al., 1997; Renne et al., 1996b; 
Staskus et al., 1997; Zhong et al., 1996). Productive infection by herpesviruses leads 
to cell lysis, which obviously contradicts the ability of a virus to transform the infected 
host cell. Thus, assigning the expression of individual KSHV ORFs to the latent or 
lytic cycle is decisive for predicting their potential roles in the pathogenesis of the 
disease. This was markedly facilitated by the ease of culturing PEL cells latently 
infected with KSHV, and inducing lytic reactivation with common laboratory 
chemicals (such as phorbol esters or sodium butyrate). If the cells are normally 
passaged (i.e., most cells are latently infected), the virus is maintained as a latent 
episome, with highly restricted viral gene expression and lack of virus production. 
Chemically induced, viral gene expression switches from the latent program to an 
ordered cascade of lytic gene expression, leading to viral replication, virion 
production, cell lysis, and viral release (Renne et al., 1996a; Renne et al., 1996b; 
Sarid et al., 1998; Zhong et al., 1996). However, the classification of a viral gene as 
latent or lytic solely by analysis of RNA expressed in bulk PEL cultures has been 
complicated by the fact, that a characteristic small percentage of every cultured PEL 
population spontaneously undergoes lytic reactivation (Renne et al., 1996b; Zhong et 
al., 1996). To overcome this problem, in situ hybridization was performed with KS 
specimens, revealing that the kaposin gene (ORF K12, later referred to as kaposin A 
[Sadler et al., 1999]) was expressed in at least 85% of spindle cells, while 
ORF25/MCP, a lytic structural protein in PELs that is highly conserved in 
Herpesviridae, was expressed in no more than 10% of the spindle cells (Nealon et 
al., 2001; Staskus et al., 1997). Due to this approach, kaposin was classified as a 
latent gene, and provided a seminal paradigm for classifying expression of other 
KSHV genes (Staskus et al., 1997). Further genome-wide analyses of KSHV gene 
expression, utilizing PEL models, compared the gene transcription patterns of each 
viral ORF during normal culture of PELs to the response to TPA treatment and lytic 
viral induction (Sarid et al., 1998). On this basis each viral ORF was classified as 
class I (detected under standard growth conditions, no induction upon TPA 
treatment), class II (detected without TPA and further induced by TPA addition), or 
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class III (undetectable without TPA but induced by the chemical), respectively. This 
examination revealed a cluster of three class I genes, LANA-1 (latency-associated 
nuclear antigen-1), ORF72 (viral cyclin D) and K13 (fas-ligand IL-1 β-converting 
enzyme inhibitory protein [v-Flip]), whose wide expression in KS specimens confirms 
their latent classification (Davis et al., 1997; Dittmer et al., 1998). However, the 
detection of kaposin A as a class II gene in these cells demonstrates that not all 
latent genes are class I (Sarid et al., 1998; Sadler et al., 1999; Staskus et al., 1997). 
The group of class II genes typically consisted of herpesvirus regulatory and viral 
DNA replicative genes, as well as most of the viral homologs of cellular genes. The 
class III genes, in contrast, encoded primarily typical late (L) genes, such as viral 
structural and replication genes (Sarid et al., 1998). More recent studies based on 
DNA microarrays have enabled simultaneous comparisons of the transcription 
kinetics of quasi all KSHV genes (Dittmer, 2003; Jenner et al., 2001; Paulose-Murphy 
et al., 2001). Besides confirming the original PEL-based classifications of the viral 
genes based on the addition of TPA, microarrays are for example also a powerful 
means to determine the kinetics of first appearance and peak expression of the lytic 
genes.  
Gene expression studies after reactivation of latent virus have identified immediate 
early (IE) transcripts (typical for regulatory genes of herpesviruses) based on their 
resistance to treatment with cycloheximide (Sun et al., 1999). One of these 
transcripts is the ORF50 (replication and transcriptional activator [Rta]), whose 
expression product is able to reactivate the virus from latency in PEL cells (Gradoville 
et al., 2000; Lukac et al., 1998; Lukac et al., 1999; Sun et al., 1998). The ORF50 is 
tricistronic and also encodes the downstream genes K8/K-bZIP/RAP and K8.1 
(Gruffat et al., 1999; Lin et al., 1999; Lukac et al., 1998; Seaman et al., 1999; Sun et 
al., 1998; Sun et al., 1999; Zhu et al., 1999). Investigations of transcript architecture 
from individual loci revealed that numerous KSHV transcripts are spliced and many 
are polycistronic. 
Interestingly, the low level of spontaneous lytic gene expression detected against the 
backdrop of latent expression in most PEL cultures is highly similar to what is found 
in KS clinical samples (Fakhari and Dittmer, 2002; Jenner et al., 2001; Paulose-
Murphy et al., 2001; Sarid et al., 1998). This is most likely not an artefact of tissue 
culture models, since most infected cells in KS specimens display a latent KSHV 
gene expression with occasional cells expressing lytic transcripts (Chan et al., 1998; 
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Dupin et al., 1999; Katano et al., 2000; Lin et al., 1998; Orenstein et al., 1997; 
Parravicini et al., 2000; Staskus et al., 1997; Sun et al., 1999). More recent 
experiments of de novo infection of cultured endothelial cells have also demonstrated 
a similar mixture of latent and lytic gene expression (Ciufo et al., 2001; Lagunoff et 
al., 2002; Moses et al., 1999). 
 
 
2.3.5 Kaposin  
 
At the right end of the KSHV genome a cluster of latently expressed proteins can be 
found, where besides the latency-associated nuclear antigens, v-cyclin and v-FLIP 
also the K12 locus is located (Dittmer et al., 1998). 
The K12 locus is divergent and consists of the K12 ORF and two upstream sets of 23 
nucleotide direct repeats DR2 and DR1. Surprisingly, Sadler and colleagues 
presented evidence that these direct repeats are expressed on the protein level in 
KSHV-infected cells despite the absence of AUG start codons (Sadler et al., 1999). 
They immunized mice against PEL tumor cells to generate monoclonal antibodies 
and found that approximately half of the mabs were directed against DR repeats. By 
tagging the DR repeats at the 3’ end, they could show that all reading frames are 
expressed and speculate that different kaposin protein isoforms are expressed 
initiating from distinct start codons using different reading frames. These isoforms 
derived either from ORF K12 itself or from the repetitive elements upstream of ORF 
K12 were termed kaposin A, B, and C (Fig. 6A). While kaposin A is initiated from the 
only predicted translational start codon within the locus, the AUG codon at the 5’ end 
of K12, putative CUG or GUG alternative start codons, can be found in or 5’ of the 
DR1 and DR2 repeats. Both direct repeat regions lack stop codons in all three 
reading frames. The open reading frames 2 and 3 run into stop codons between the 
DR repeats and ORF K12. In contrast, reading frame 1 is open to the 3’ end of K12. 
Intriguingly, translation of DR2 and DR1 results in a 23-amino acid peptide of 
common sequence in all three reading frames (Fig. 6B). In Western blot analyses 
Sadler and colleagues detected proteins of 54, 48, 38 and 32 kd, of which kaposin B 
(containing the DR repeats but not K12) with a size of approximately 48 kd is the 
major protein expressed. Based on the structural sequence information and incited 
by these results, they hypothesized that (i) internal ribosomal entry is caused by the 
DR repeat region enabling the expression of K12, (ii) more translational products 
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may be produced, (iii) isoforms containing K12 sort to a different subcellular 
compartment as the other isoforms, (iiii) the different isoforms could produce 
differences in activity or stability, (v) one of the kaposin isoforms is a regulatory 
molecule whose expression at high levels is not compatible with cell survival or 
growth and that (vi) the complex translational control is mandatory to titrate 
expression levels of this toxic product down.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Coding potential of the K12 locus 
(A) CUG and GUG alternative translation initiation codons are indicated with the reading frame and 
size of the resultant translation products for a BCBL-1 mRNA. Additional CUGs are present within 
each DR1 repeat in all three reading frames. T0.7, see text (B) Translation of DR1 and DR2 (not 
shown) results in a repeating 23 aa peptide of common sequence in all three reading frames. The 
single letter code of DR1 is shown below the appropriate reading frame of the mRNA sequence. The 
23 aa repeats are encoded by three 23-nt repeats (23 nuc). CUGs are shown in read. The leucine 
residue was randomly assigned as the start of each repeat and is coloured red in each reading frame 
(according to Sadler et al., 1999). 
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The genomic sequence between the start sites and the K12 ORF is highly 
polymorphic and varies markedly in number of direct repeats between different KS 
specimens and PEL cell lines. Transcription of this locus produces mRNAs that vary 
in length in different isolates (Sadler et al., 1999). Whereas the first identified gene 
product of this locus, kaposin A, was originally reported to be expressed by a 0.7 kb 
mRNA (T0.7), later reports identified several longer transcripts of up to 2.4 kb in KS 
and PEL cells harboring the upstream repeat regions. Therefore, the translation 
initiation of kaposin A at the AUG start codon of the K12 ORF was predicted to 
involve leaky ribosomal scanning or internal translational initiation from transcripts 
containing the upstream repetitive sequences (Sadler et al., 1999; Zhong et al., 
1996). Recent data presented by Li and colleagues have identified a spliced 
transcript that includes a 5’ non-coding exon derived from a region between ORFs 72 
(v-cyclin) and 73 (LANA), approximately 5 kbp upstream of the 5’ end of the 
previously identified kaposin B/C transcripts (Li et al., 2002). This splicing effect 
appears to be common to PEL and KS tissue and several PEL cell lines. It is thus 
possible that kaposin transcripts are produced from either of two promoters (Li et al., 
2002; Sadler et al., 1999). Since the K12 locus expresses abundant kaposin 
transcript(s) during latency in KS tissue and PEL cells, but is also strongly induced 
following lytic reactivation, it was hypothesized that the encoded proteins may 
mediate functions that serve both replication modes (Sadler et al., 1999; Staskus et 
al., 1997; Sturzl et al., 1997; Zhong et al., 1996). The proximal kaposin B/C promoter 
driving the unspliced transcript is highly responsive to the immediate early ORF50 
transactivator, which binds directly or indirectly to this region (Chang et al., 2002). 
The finding that kaposin can be expressed during the latent phase of infection 
suggests that it contributes to KSHV-associated malignancies. This hypothesis was 
supported by the results from functional analyses of the hydrophobic 60 aa protein 
kaposin A, which was found to be transforming in vitro in Rat-3 fibroblasts and in vivo 
in nude mice (Kliche et al., 2001; Muralidhar et al., 1998). In transduced Rat-3 cells 
kaposin A was shown to be localized in the cytoplasm, and it was proposed that 
kaposin A is Golgi-associated (Muralidhar et al., 1998; Muralidhar et al., 2000). More 
recent data from confocal microscopy and subcellular fractionation experiments 
indicate that kaposin A has a predominantly perinuclear localization in PEL cells and 
transfected NIH3T3 cells. As indicated by kaposin A-specific immunostaining of non-
permeabilised cells detected by flow cytometry, kaposin A can also distribute to the 
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plasma membrane (Kliche et al., 2001; Tomkowicz et al., 2002). This result coupled 
with secondary structure predictions and hydrophobicity plots for the 60 aa protein 
suggested that kaposin A is a type II transmembrane protein with an extracellular c-
terminal domain (Kliche et al., 2001). The kaposin A-induced transformation is 
mediated through a direct interaction of kaposin A with cytohesin-1, a guanine 
nucleotide exchange factor (GEF) for ADP-ribosylation factors (ARF), which leads to 
an activation of MAP kinases. The transformed phenotype shown by actin 
remodeling, focus formation and gene activation, was reverted by a cytohesin-1 
E157K mutant, which is deficient in catalyzing the guanine nucleotide exchange. 
Kaposin A was shown to activate cytohesin-1 by recruitment to the cell membrane, 
similar to phosphatidylinositol-mediated GEF recruitment and activation, which 
subsequently stimulates the ARF GTPase (Kliche et al., 2001). 
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2.4 Aim of this study 
 
The K12 locus is a complex genomic region, which consists of the ORF K12 and two 
sets of upstream direct repeats. Whereas previous studies focused on kaposin A 
(ORF K12) and its function, little is known about the expression of other protein 
products originating from this locus (Kliche et al., 2001; Muralidhar et al., 1998). 
Sadler and colleagues showed that the upstream repeat region is expressed on the 
protein level in both, PEL cell lines and KS tumors (Sadler et al., 1999). They 
hypothesized that a variety of translational products is expressed from the K12 locus. 
Furthermore, they suggested that internal ribosomal entry is caused by the DR 
repeat region, that different isoforms may produce differences in activity or stability 
and that one or more of the kaposin isoforms are regulatory molecules whose 
expression is titrated by the complex translational control.  
The aim of this work was to characterize biochemically and functionally the lytical 
kaposin protein isoforms generated in the PEL cell line BCBL-1. The concept of the 
present study was first to create molecular tools, qualifying to address the following 
questions: (i) the analysis and resolution of the expression pattern including the 
determination of the cellular localization, (ii) the biochemical characterization, (iii) the 
investigation of functional properties, (iv) the search for interaction partners and, 
finally, (v) the mutual influence of different isoforms on each other. 
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3 MATERIALS AND METHODS 
 
3.1 Materials 
 
3.1.1 Equipment 
Bacterial Shaker      Kühner, Bürsfelden, Switzerland 
Balances       Sartorius, Göttingen, Germany 
Centrifuge GP      Beckman, Palo Alto, USA 
Centrifuge J2-21      Beckman, Palo Alto, USA 
Centrifuge Varifuge 3.0R     Heraeus, Hanau, Germany 
Centrifuge Minifuge RF     Heraeus, Hanau, Germany 
Centrifuge Labofuge T     Heraeus, Hanau, Germany 
Centrifuge, refrigerated and non-refrigerated  Heraeus, Hanau, Germany 
 Confocal laser scanning microscope  Leica, Bensheim, Germany 
 Confocal laser scanner   Leica, Bensheim, Germany 
Eagle eye  Stratagene, Amsterdam, The 
Netherlands 
Elisa Reader  Tecan Labinstruments, Crailsheim, 
Germany 
Film developing machine   Optimax Typ TR MS Laborgeräte, 
Heidelberg, Germany 
Fluorescence/light microscope Axiovert 35  Zeiss, Oberkochen, Germany 
Fluorescence/light microscope Axiovert 200M  Zeiss, Oberkochen, Germany 
Fridge (4°C)       Liebherr, Ochsenhausen, Germany 
Freezer (-20°C)      Liebherr, Ochsenhausen, Germany 
Freezer (-80°C)  Forma Scientific, Inc., Marietta, Ohio, 
USA 
Cryo 1°C Freezing Container    Nalgene Nunc, Wiesbaden, Germany 
Gel dryer       Bio-Rad, Munich, Germany 
GelAir drying system     Bio-Rad, Munich, Germany 
Incubators for cell culture (37°C)  Forma Scientific, Inc., Marietta, Ohio, 
USA 
Inverted microscope TMS     Nikon, Düsseldorf, Germany 
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Laminar Flow Hood Steril Gard II A/B3  The Baker Company, Sanford, 
Maine,USA  
Magnetic stirrer with heating block   Janke & Kunkel, Staufen, Germany 
Microwave       AEG, Berlin, Germany 
Overhead mixer      Heidolph, Schwabach, Germany 
PCR Thermal Cycler GeneAmp 2400   Perkin Elmer, Weiterstadt, Germany 
pH-Meter       WTW, Weilheim, Germany 
Photometer Gene Quant II    Pharmacia/LKB, Freiburg, Germany 
Pipettes       Gilson, Villies Le Bel, France; 
Eppendorf, Hamburg, Germany 
Pipetting aid       Technomara, Zürich, Switzerland 
Electrophoresis Power supply EPS200  Amersham-Pharmacia, Freiburg, 
Germany 
Sonifier 450  Branson Ultrasonics Corp., Danbury, 
USA 
Thermomixer      Eppendorf, Hamburg, Germany 
UV-transilluminator (366 nm)    Vetter, Wiesloch, Germany 
   (254 nm)    Konrad Benda, Wiesloch, Germany 
Vortex mixer      IKA Works, Inc, Wirmington, USA 
Water bath       Julabo, Seelbach, Germany 
       GFL, Burgwedel, Germany 
 
 
3.1.2 Chemicals 
 
Acetic Acid       Roth, Karlsruhe, Germany 
Acrylamide/Bisacrylamide 37,5/1   Roth, Karlsruhe, Germany 
(Rotiphorese Gel 30)   
Agar for plates  BD Biosciences Clontech, Heidelberg, 
Germany 
Agarose electrophoresis grade   Invitrogen, Karlsruhe, Germany 
Ammonium persulfate (APS)    Sigma, Munich, Germany 
Ampicillin  Roche Diagnostics, Mannheim, 
Germany 
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Bacto peptone  BD Biosciences Clontech, Heidelberg, 
Germany 
Bacto tryptone  BD Biosciences Clontech, Heidelberg, 
Germany 
Bacto yeast extract     BD Biosciences Clontech, Heidelberg, 
       Germany 
Bicine       Sigma, Munich, Germany 
Bromophenol blue      Serva, Heidelberg, Germany 
Bovine serum albumin (BSA)    Sigma, Munich, Germany 
Calcium chloride      Merck, Darmstadt, Germany 
Chloramphenicole     Sigma, Munich, Germany 
Coomassie brilliant blue R-250   Bio-Rad, Munich, Germany 
Dextrose       BD Biosciences Clontech, Heidelberg, 
       Germany 
Dimethylsulfoxide (DMSO)    Merck, Darmstadt, Germany 
Disodiumhydrogenphosphate   Merck, Darmstadt, Germany 
Dithiothreitol (DTT)      Roth, Karlsruhe, Germany 
dNTPs  Roche Diagnostics, Mannheim, 
Germany 
DMF (N,N-dimethylformamide)    Sigma, Munich, Germany 
DO (dropout) supplements   BD Biosciences Clontech, Heidelberg, 
       Germany 
Dulbecco’s modified Eagle’s medium (DMEM) Gibco BRL, Karlsruhe, Germany 
Ethanol (EtOH)      Riedel-de Haën, Seelze, Germany 
Ethidium bromide      Sigma, Munich, Germany 
Ethylenediamintetraacetate disodium salt  Roth, Karlsruhe, Germany 
(EDTA) 
Ethylene glycol      Sigma, Munich, Germany 
Fetal calf serum (FCS)      Gibco BRL, Karlsruhe, Germany 
Glucose      Merck, Darmstadt, Germany 
Glutathione-Sepharose 4B Amersham-Pharmacia, Freiburg, 
Germany 
Glycerol       Roth, Karlsruhe, Germany 
Glycine       Serva, Heidelberg, Germany 
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Histogel      Linaris, Wertheim-Bettingen, Germany 
Hydrochloric acid (HCl)     Merck, Darmstadt, Germany 
Interferon (IFN)  PBL Biomedical Laboratories, 
Piscataway, USA 
Imidazole       Fluka, Seelze, Germany 
Ionomycin      Sigma, Munich, Germany 
Isopropanol       Riedel-de Haën, Seelze, Germany 
Isopropylthio-b-D-galactosid (IPTG)   Roth, Karlsruhe, Germany 
Kanamycin       Serva, Heidelberg, Germany 
L-glutamine       Gibco BRL, Karlsruhe, Germany 
L-Glutathione (reduced)     Sigma, Munich, Germany 
Magnesium chloride     Merck, Darmstadt, Germany 
Magnesium sulfate      Merck, Darmstadt, Germany 
2-mercaptoethanol      Merck, Darmstadt, Germany 
Methanol       Merck, Darmstadt, Germany 
N-butyrate      Sigma, Munich, Germany 
Nonidet P40 (NP-40)     Fluka, Seelze, Germany  
Pefabloc  Roche Diagnostics, Mannheim, 
Germany 
Polyethylene glycol (PEG 1000)    Sigma, Munich, Germany 
Penicillin-Streptomycin     Gibco BRL, Karlsruhe, Germany 
Phenylmethylsulfonfluoride (PMSF)  Roche Diagnostics, Mannheim, 
Germany 
Phosphate buffered saline (PBS)  Dulbecco’s Gibco BRL, Karlsruhe, 
Germany 
Ponceau S       Sigma, Munich, Germany 
Potassium acetate      Riedel-de Haën, Seelze, Germany 
Potassium chloride      Merck, Darmstadt, Germany 
Protein G-Sepharose Fast Flow  Amersham-Pharmacia, Freiburg, 
Germany 
Rosswell Park Memorial Institute (RPMI)1640  Gibco BRL, Karlsruhe, Germany 
SD Base medium BD Biosciences Clontech, Heidelberg, 
Germany 
Skim milk powder      Merck, Darmstadt, Germany 
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Sodium acetate      Riedel-de Haën, Seelze, Germany 
Sodium azide      Serva, Heidelberg, Germany 
Sodium chloride      Riedel-de Haën, Seelze, Germany 
Sodium dodecylsulfate (SDS)    Merck, Darmstadt, Germany 
Sodium hydroxid      J.T.Baker B.V., Deventer, Holland 
Sorbitol Sigma, Munich, Germany 
Tetramethylethylenediamin (TEMED)  Amersham-Pharmacia, Freiburg, 
Germany 
12-O-tetradecanoylphorbol-13-acetate (TPA) Sigma, Munich, Germany 
Tris(hydroxymethyl)aminomethan (Tris)  Roth, Karlsruhe, Germany 
Triton X-100       Serva, Heidelberg, Germany 
Trypsin       Gibco BRL, Karlsruhe, Germany 
Tween 20       Merck, Darmstadt, Germany 
Urea        Roth, Karlsruhe, Germany 
Western Blue Stabilized Substrate for  Promega, Mannheim, Germany 
Alkaline Phosphatase        
X--Gal       BD Biosciences Clontech, Heidelberg, 
       Germany 
 
 
3.1.3 Additional materials 
 
Autoradiography films BIOMAX-MR   Eastman-Kodak, Rochester, USA 
Cell culture plastic ware     Greiner, Nürtingen, Germany 
Nunc, Wiesbaden, Germany 
Falcon/Becton Dickinson, Heidelberg, 
Germany 
Filter paper (3 mm)     Whatman Ltd., Maidstone, England 
Glass slides for IF  Marienfeld, Bad Mergentheim, 
Germany 
Protran nitrocellulose transfer membranes  Schleicher & Schuell, Dassel, 
Germany 
Sterile filter units      Millipore 
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3.1.4 Cell lines 
 
293     human embryonal kidney cell line (ATCC: CRL-1573) 
HeLa      human cervix carcinoma (ATCC :CCL-2) 
BCBL-1 body cavity-based lymphoma cell line, kindly provided by 
Dr. Don Ganem, USCF, San Francisco, USA 
 
 
3.1.5 Recombinant vaccinia viruses 
 
Recombinant vaccinia virus expressing kaposin A, vKapA, was generated as 
reported previously (Kliche et al., 2001). Recombinant vaccinia virus vTF-7 
expressing T7 polymerase was provided by the NIH AIDS reagent program (Fuerst et 
al., 1986).  
 
 
3.1.6 Bacterial strains 
 
DH5     Gibco BRL, Karlsruhe, Germany 
BL21 RIL kindly provided by Dr. K.-P. Hopfner, Genzentrum, 
München, Germany  
 
 
3.1.7 Yeast strains 
 
AH109  BD Biosciences Clontech, Heidelberg, Germany 
 
 
3.1.8 Plasmids 
 
pBCBL-1-XhoII-NheI kindly provided by Dr. Don Ganem, USCF, San 
Francisco, USA  
p53wt (Hoppe-Seyler and Butz, 1993) 
pCDNA 3.1 zeo Grb2 f. l. kindly provided by Dr. Hermann Schätzl, TU, München, 
Germany 
pCR3 Invitrogen, Karlsruhe, Germany 
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pCRE-Luc Stratagene, Amsterdam, The Netherlands 
pCR3Ig0.2 (Kliche et al., 2001) 
pCR3kapB this study 
pCR3kapD this study 
pCR3kapE this study 
pEGFP-C1  BD Biosciences Clontech, Heidelberg, Germany 
pEGFP-kapB this study 
pEGFP-DR2 this study 
pEGFP-DR1 this study 
pEGFP-DR2-NLS this study 
pET-15b Novagen, Madison, USA 
pET-DR2 this study 
pGADT7 BD Biosciences Clontech, Heidelberg, Germany 
pGADT7-kapB this study 
pGADT7-DR2 this study 
pGADT7-DR1 this study 
pGADT7-Grb2-C-SH3 kindly provided by Dr. Hermann Schätzl, TU, München, 
Germany 
pGBKT7 BD Biosciences Clontech, Heidelberg, Germany 
pGBKT7-kapB this study 
pGBKT7-DR2 this study 
pGBKT7-DR1 this study 
pGBKT7-Grb2 f. l. this study 
pGBKT7-Grb2 C-SH3 this study 
pGEX-4T-1 Amersham-Pharmacia, Freiburg, Germany 
pGEX-DR2 this study 
pGEX-DR1 this study 
pHIVluc (Holloway et al., 2000) 
p-IL6 kindly provided by Gergana Iotzova, Genzentrum, 
München, Germany 
pISRE-Luc Stratagene, Amsterdam, The Netherlands 
pNFB-Luc Stratagene, Amsterdam, The Netherlands 
pUC21 New England Biolabs, Beverly, USA 
pRK5c-mycRasV12 kindly provided by Dr.Alan Hall, MRC, London, UK 
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pRTU1 and pRTU14 kindly provided by Dr. Arndt Kieser, GSF, München, 
Germany 
pSV2tat72 NIH AIDS reagent program 
pTIT-GFP kindly provided by Dr. Karl-Klaus Conzelmann, Gene 
Center, München 
p53-Luc Stratagene, Amsterdam, The Netherlands 
pSRE-Luc Stratagene, Amsterdam, The Netherlands 
pVEGF1-Luc kindly provided by Dr. Werner Risau, MPI für 
physiologische und klinische Forschung, Bad Nauheim, 
Germany 
 
 
3.1.9 Oligonucleotides 
 
name sequence (5’3’) 
NsiI/3xStop/XhoI for TGGATAGAGGCTTAACGTGAC  
NsiI/3xStop/XhoI rev TCGAGTCACGTTAAGCCTCTATCCATGCA 
NLS NsiI/XhoI for TCCCCAAGAAGAAGCGCAAGGTGTAGC 
NLS NsiI/XhoI rev TCGAGCTACACCTTGCGCTTCTTCTTGGGGATGCA 
 
The oligonucleotides were obtained from metabion (Martinsried, Germany) and 
Thermo hybaid (Ulm, Germany). 
 
 
3.1.10 Molecular weight markers 
 
Gene Ruler 100 bp DNA ladder     MBI Fermentas, St. Leon-Rot, 
Germany 
Gene Ruler DNA 1 kb ladder   MBI Fermentas, St. Leon-Rot, 
Germany 
See blue plus 2 prestained protein standard  Invitrogen, Karlsruhe, Germany 
low range 
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3.1.11 Kits 
 
BCA Protein Assay     Pierce, Rockford, USA 
Dual-Luciferase® Reporter Assay System Promega, Mannheim, Germany 
ECL western blotting detection system  Amersham-Pharmacia, Freiburg, 
Germany 
Effectene Transfection Reagent  Qiagen, Hilden, Germany 
Luciferase Assay System Promega, Mannheim, Germany 
Pharmacia GFX PCR DNA Gel Purification Amersham-Pharmacia, Freiburg, 
Kit       Germany 
Qiafilter Plasmid Maxi Kit  Qiagen, Hilden, Germany 
 
 
3.1.12 Antibodies 
 
3.1.12.1 Primary antibodies 
 
kap-4F11(IgG2a)  rat mab against the c-terminal domain of K12 
    (Kliche et al., 2001) 
kdr1-3C12(IgG2a)  rat mabs against DR1; this study 
kdr1-8D10(IgG1) 
kdr2-4C6(IgG1)  rat mabs against DR2; this study 
kdr2-6H8(IgG1) 
3F10  rat mab against HA Tag, Roche Diagnostics, Mannheim, 
Germany  
9E10  mouse mab against Myc Tag, Santa Cruz Biotechnology, 
Heidelberg, Germany 
B-14  mouse mab against GST (B14), Santa Cruz 
Biotechnology, Heidelberg, Germany 
C-16  rabbit polyclonal antiserum against 14-3-3, Santa Cruz 
Biotechnology, Heidelberg, Germany 
M-20 goat polyclonal serum against lamin B , Santa Cruz 
Biotechnology, Heidelberg, Germany 
SPA-860  rabbit polyclonal antiserum against calnexin, Stressgen   
Biotechnlogies Corp., BC, Canada 
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VAP-SV044  rabbit polyclonal antiserum against Grb2, Stressgen 
Biotechnlogies Corp., BC, Canada 
 
 
3.1.12.2 Secondary antibodies 
 
TIB173-FITC conjugated  mouse mab against rat IgG2a 
TIB170-biotinylated   mouse mab against rat IgG1 
alkaline phosphatase-conjugated: 
goat anti-rat     Jackson, Hamburg, Germany 
peroxidase-conjugated: 
donkey anti-goat   Jackson, Hamburg, Germany 
goat anti-rat     Jackson, Hamburg, Germany 
goat anti-rabbit   Jackson, Hamburg, Germany 
goat anti-mouse   Jackson, Hamburg, Germany 
 
 
3.1.13 Enzymes 
 
T4 DNA Polymerase   New England Biolabs, Beverly, USA 
Calf Intestinal Alkaline   New England Biolabs, Beverly, USA 
Phosphatase (CIP)    
T4 DNA Ligase    MBI Fermentas, St. Leon-Rot, Germany 
AmpliTaq Gold® DNA  Applied Biosystems, Foster City, CA, USA 
Polymerase 
T4 Polynukleotid kinase  New England Biolabs, Beverly, USA 
Restriction Endonucleases MBI Fermentas, St. Leon-Rot, Germany 
Roche Diagnostics, Mannheim, Germany 
New England Biolabs, Beverly, USA 
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3.2 Methods 
 
3.2.1 Bacterial culture 
 
3.2.1.1 Cultivation of bacteria 
 
E. coli bacteria were grown in LB medium or on LB agar plates. Incubation was 
performed at 37°C with constant shaking. 
LB medium (1 l):    10 g Bacto tryptone 
  5 g Bacto yeast extract 
  5 g NaCl 
LB agar:     LB medium with 1.5 % agar 
Selection medium:   LB medium with 100 µg/ml ampicillin and/or 50 
µg/ml kanamycin 
 
 
3.2.1.2 Preparation of competent bacteria 
 
For preparation of competent bacteria a single clone of DH5 was picked and grown  
in 20 ml TYM medium at 37°C to an OD600nm of 0.8. The bacterial culture was diluted 
with 100 ml TYM and incubated at 37°C until an OD600nm between 0.5-0.9 was 
reached. Subsequently the culture was again diluted by adding 500 ml of TYM and 
incubated at 37°C. At an OD600nm of 0.6 the culture was rapidly chilled down on ice 
water. The following incubations were all performed at 4°C or on ice. The bacteria 
were distributed to two 50 ml tubes and centrifuged 5 min at 3500 rpm (Heraeus 
Varifuge 3.0R). The supernatants were discarded and the pellets were resuspended 
in 100 ml icecold TfB I. After 40-50 min incubation on ice, the bacteria were 
centrifuged 10 min at 2500 rpm (Heraeus Varifuge 3.0R). The supernatants were 
discarded and the pellets were resuspended in 25 ml ice-cold TfB II. Aliquots of 0.4 
ml were added to precilled 0.5 ml reaction tubes and stored at –80°C. 
 
TYM:      10 mM MgS04 
         100 mM NaCl 
20 g/l Bacto tryptone 
  5 g/l Bacto yeast extract 
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TfB I:     30 mM KAc 
     50 mM MnCl2 
             100 mM KCl 
     10 mM CaCl2 
     15 % (v/v) Glycerol 
TfB II:     10 mM MOPS pH 7.0 
     75 mM CaCl2 
     10 mM CaCl2 
     15 % (v/v) Glycerol 
 
both buffers sterilized by filtration (Ø 0.2 µm) and stored at 4°C. 
 
 
3.2.1.3 Transformation 
 
Different volumes of the ligation reaction mixture (5, 10, 20 µl) were added to 100 µl 
competent bacteria, mixed with 80 µl of 50 mM CaCl2 and incubated 30 min on ice. 
After the heat shock, 1 min 42°C, 800 µl LB medium were added and bacteria were 
cultivated for 1 h at 37°C. Then 100 µl were taken and plated on LB agar plates with 
antibiotic(s). The residual bacteria were centrifuged (4000 g, 5 min), resuspended 
and plated the same way. The plates were incubated o/n at 37°C. 
 
 
3.2.2 DNA techniques 
 
3.2.2.1 Purification of plasmid DNA 
 
Plasmid DNA was purified with the Pharmacia GFX Micro Plasmid Kit in small scale 
and the Qiafilter Plasmid Maxi Kit in large scale according to the manufacturer’s 
instructions. 
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3.2.2.2 Determination of DNA concentration 
 
The concentration and purity of the purified DNA was determined by measuring the 
UV absorbance at 260 and 280 nm. The DNA concentration was calculated with the 
OD260nm  (1 OD260nm = 50 µg/ml dsDNA or 33 µg/ml ssDNA). The purity was 
estimated with the OD260nm/OD280nm ratio, with a ratio of approximately 1.8 indicating 
a low degree of protein contamination. 
 
 
3.2.2.3 Restriction endonuclease digestion 
 
Restriction endonuclease reactions were performed according to the manufacturer’s 
recommendations. In general, 1.5 µg DNA were digested for 2 h at the respective 
temperature with 10-20 U enzyme. Efficacy of the cleavage reaction was controlled 
by agarose gel electrophoresis. 
 
 
3.2.2.4 Oligonucleotide phosphorylation and annealing 
 
Single stranded oligonucleotides were phosphorylated o/n at 37°C o/n with T4 
Polynukleotid kinase. 
Reaction mixture: 
1.5 µl oligonucleotide (150 pMol) 
2 µl 10 mM ATP 
2 µl 10x PNK buffer (700 mM Tris-HCl (pH 7.6), 100 mM MgCl2, 50 mM dithiothreitol) 
1 µl T4 Polynukleotid kinase (10 U) 
13.5 µl H2O 
 
For annealing the phosphorylation mixtures of complementary oligonucleotides were 
combined and diluted to 200 µl in H2O. The reaction tube was boiled in 500 ml of H2O 
for 5 min and allowed to cool down to RT. Subsequently, the oligos were precipitated 
by ethanol precipitation as described below and resolved in an appropriate amount of 
H2O before used in ligation. 
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3.2.2.5 5’-Dephosphorylation reaction 
 
5’-dephosphorylation reaction of plasmid vector DNA after restriction endonuclease 
cleavage was performed with the calf intestinal alkaline phosphatase (CIP). 50 U CIP 
were added to about 1.5 µg restriction enzyme digested plasmid DNA. After 30 min 
incubation at 37°C was stopped and the DNA was isolated by agarose gel 
electrophoresis. 
 
 
3.2.2.6 Polymerase chain reaction (PCR) 
 
Polymerase Chain Reaction (PCR) was performed with the AmpliTaq Gold® DNA 
polymerase from Thermus aquaticus to verify the cloning of the oligonucleotides 
(containing stop codons or a NLS, see 2.1.8) into the plasmids pCR3kapB and 
pEGFP-DR1-NLS, respectively. 
The reaction mixture contained: 
5 µl 10x PCR Buffer (100 mM Tris-HCl pH 8.3, 500 mM KCl, 15 mM MgCl2, 0,01% 
gelatine w/v.) 
1 µl 10 mM dNTPs (200 µM each) 
1 µl forward primer (150 pMol) 
1 µl reverse primer (150 pMol) 
1 µl AmpliTaq Gold® (5U) 
21 µl H2O 
+ 20 µl template DNA in H2O (bacteria pools) 
Bacteria colonies were picked with pipette tips from plates and transfered into a PCR 
tube containing 20 µl of H2O. Subsequently, the tubes were boiled for 10 min at 94°C 
before adding the PCR reaction mixture. 
 
The following cycles were performed: 
1. 94°C 5 min 
2. 94°C 1 min 
3. 55°C 1 min         10x with 1°C decrease per cycle to 45°C (touchdown), then 30x 
4. 72°C 2 min 
5. 72°C min 10 min 
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3.2.2.7 Isolation of DNA fragments 
 
DNA fragments were separated by agarose gel electrophoresis, stained with 
ethidium bromide and detected with UV light (366 nm). The gel slice containing the 
DNA fragments was cut out and the DNA was isolated using the Pharmacia GFX 
PCR DNA Gel Purification Kit according to the manufacturer’s instructions. 
 
 
3.2.2.8 Phenol/chloroform extraction and ethanol precipitation 
 
Proteins were removed from DNA preparations by extracting twice with 1x volume 
phenol/chloroform and once with 1x volume chloroform. After vigorous vortexing for 
10 s the solution was centrifuged at 14000 rpm (microcentrifuge) for 1 min and the 
upper DNA containing phase was recovered. Then 0.1x volume 3 M NaAc pH 5.2 
and 2.5x volume 100% EtOH (cold) were added, and incubation at –80°C was 
performed for 20 min. The precipitated DNA was centrifuged down at 14000 rpm for 
30 min (4°C). Then the pellet was washed once with 70% EtOH (cold). After another 
centrifugation step (14000 rpm, 15 min, 4°C, microcentrifuge) the EtOH was carefully 
removed, the pellet air-dried at RT and finally resuspended in H2O.  
 
 
3.2.2.9 Ligation 
 
For ligation about 50 ng vector DNA was used with a molar ration of vector/insert of 
about 1:3. The reaction was performed in a total volume of 20 µl 1x reaction buffer 
(MBIFermentas) with 5 U T4 DNA Ligase (MBI Fermentas). First vector and insert 
were mixed in reaction buffer, then the ligase was added. After incubation o/n in a 
watherbath at 16°C the ligation either directly transformed into competent bacteria or 
stored at –20°C until further usage. 
 
 
3.2.2.10 Agarose gel electrophoresis 
 
Analysis of DNA fragments and plasmids was performed by agarose gel 
electrophoresis in 1x TAE. In general, agarose concentration was between 1 and 3 % 
in 1x TAE. The agarose was solubilized by heating in a microwave oven. Ethidium 
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bromide was added to a final concentration of 0.25 µg/ml (2,5 µl stock to 100 ml) just 
before pouring the gel. Probes were mixed with 0.17x volume loading buffer. Gels 
(6.5 x 9.5 cm) were run horizontally at 80-120 V. DNA was detected with UV light, 
=254 nm or =366 nm to cut out specific fragments. 
 
loading buffer (6x in water)  MBI Fermentas, St. Leon-Rot, Germany 
20x TAE:     800 mM Tris 
400 mM NaAc 
  40 mM EDTA 
adjusted to pH 7.8 with acetic acid 
Ethidium bromide (stock):   10 mg/ml 
 
 
3.2.2.11 Plasmid construction  
 
(1) pCR3kapB. A fragment containing the DR2 and DR1 repeat regions was 
subcloned from pBCBL-1-XhoII-NheI into pUC21 (New England Biolabs) using 
HindIII and NsiI restriction sites. Stop codons in each reading frame were added by 
subcloning the two oligos TGGATAGAGGCTTAACGTGAC and 
TCGAGTCACGTTAAGCCTCTATCCATGCA as adapters into the NsiI and XhoI 
restriction sites of this plasmid. Subsequently, a fragment excised by HindIII and XhoI 
was subcloned into pCR3 (Invitrogen). (2) pCR3kapD. The DR1 repeats were 
excised from pEGFP-DR1 by PstI and XhoI restriction sites and subcloned into a 
pCR3 derivative containing a HA Tag, in which K12 fragment excised with NsiI and 
XhoI from pBCBL-1-XhoII-NheI has been subcloned. (3) pCR3kapE. The DR1 
repeats (containing an AUG start codon and a HA Tag) were subcloned by BglII and 
XhoI restriction sites from pGADT7-DR1 into pCR3. (4) pEGFP-kapB. The fragment 
excised by PstI and XhoI from pCR3kapB was subcloned into pEGFP-C1 (Clontech). 
(5) pEGFP-DR2. pEGFP-kapB was digested with SmaI and religated. (6) pEGFP-
DR1. pEGFP-kapB was digested with HhaI, blunted with T4 DNA Polymerase and 
digested with XbaI. Subsequently, the fragment was ligated into pEGFP-C1 digested 
with SmaI and XbaI. (7) pEGFP-DR1-NLS. The DR1 repeats were excised by 
digestion of pEGFP-DR1 with PstI and XhoI and subcloned into pUC21. 
Subsequently, the oligos TCCCCAAGAAGAAGCGCAAGGTGTAGC and 
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TCGAGCTACACCTTGCGCTTCTTCTTGGGGATGCA encoding a SV-40 NLS and a 
stop codon were subcloned as adapters into the NsiI and XhoI restriction sites. The 
DR2-NLS fragment was eventually subloned by PstI and SacII into pEGFP-C2. (8) 
pGADT7-kapB. The fragment excised by EcoRI and XhoI from pEGFP-kapB was 
subcloned by EcoRI and XhoI restriction sites into pGADT7 (Clontech). (9) pGADT7-
DR2. The EcoRI and XhoI fragment from pEGFP-DR2 was subcloned by EcoRI and 
XhoI restriction sites into pGADT7. (10) pGADT7-DR1. The fragment excised by 
EcoRI and XhoI from pEGFP-DR1 was ligated into EcoRI/XhoI digested pGADT7. 
(11) pGBKT7-kapB. (12) pGBKT7-DR2. (13) pGBKT7-DR1. Fragments isolated from 
pEGFP-kapB, pEGFP-DR2 and pEGFP-DR1 by EcoRI and XhoI digestion were 
subcloned into pGBKT7 (Clontech) digested with EcoRI and SalI. (14) pGBKT7-Grb2 
f. l.. Grb2 f.l. was excised by BamHI and XhoI digestion from pCDNA 3.1 zeo Grb2 f. 
l. and ligated into BamHI/SalI digested pGBKT7. (15) pGBKT7-Grb2-C-SH3. 
Likewise, Grb2-C-SH3 was excised by BamHI and XhoI digestion from pGADT7-
Grb2-C-SH3 and ligated into BamHI/SalI digested pGBKT7. (16) pGEX-DR2. (17) 
pGEX-DR1. Repeat regions isolated from pEGFP-DR2 and pEGFP-DR1 by EcoRI 
and XhoI digestion were subcloned into pGEX-4T-1 (Amersham). (18) pET-DR2. 
DR2 repeats were excised by PstI/XhoI digestion of pEGFP-DR1 and ligated into 
pUC21 via the same restriction sites. From this construct the DR2 repeats were 
subcloned by NdeI and XhoI restriction sites into pET-15b (Novagen). 
 
 
3.2.3 Tissue culture 
 
3.2.3.1 Cultivation and cryoconservation 
 
The KSHV-infected PEL cell line BCBL-1 was cultured in RPMI 1640 supplemented 
with 20% fetal calf serum, 100 IU/ml penicillin, 100 µg/ml streptomycin and 2 mM L-
glutamine. For induction of the lytic viral cycle BCBL-1 cells were treated for 48 h with 
3 mM n-butyrate. 293 and Hela cells were cultured in DMEM/10% FCS plus 
supplements at 37°C and 5% CO2. For cryoconservation cells were detached with 
trypsin and centrifuged at 300 g for 5 min at 4°C. Then the cells were resuspended in 
1 ml FCS/10% DMSO (4°C) with a final concentration of 0.5-1x107 cells/ml and 
transferred to cryovials which were cooled to –80°C in a “Cryo 1°C Freezing 
Container”. From there the vials were transferred to liquid nitrogen for longterm 
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storage. Frozen aliquots were quickly thawed at 37°C in a waterbath, 10ml DMEM 
was added and after centrifugation at 300 g for 5 min the supernatant was removed. 
Subsequently cells were resuspended in complete medium and transferred to cell 
culture dishes. 
 
 
3.2.3.2 Calcium phosphate transfection 
 
For transient transfection cells were grown on 10 cm Ø dishes to 60-70% confluency. 
500 µl of 2x HBS pH 7.05 was added to a 15 ml Falcon tube. In another tube 20 µg 
DNA was combined with 500 µl 250 mM CaCl2. The tube with the 2x HBS was 
vortexed while the DNA/CaCl2 solution was added dropwise. The solution was 
incubated at RT for 15-20 min to allow the formation of the Calcium-DNA precipitate. 
Subsequently, the suspension was mixed with 6 ml fresh medium and was added to 
the cells after removal of the old medium. The next day protein expression was 
assessed by immunofluorescence. 
 
2x HBS pH 7.05:   50 mM HEPES 
1.5 mM Na2HPO4x 2 H2O 
280 mM NaCl 
12 mM Glucose 
 
 
3.2.3.3 Immunofluorescence 
 
BCBL-1 cells that have been induced for 48 h with 3 mM n-butyrate were spotted 
onto poly-L-lysine-coated coverslips. Hela cells were grown on coverslips. Cells were 
fixed with ice-cold methanol for 2 min and subsequently blocked against non-specific 
binding for 1 h with PBS/2,5% FCS. The cells were incubated with the primary 
antibody diluted in PBS/2,5% FCS for 1 h, washed four times with PBS and 
incubated with the secondary antibody (fluorescein conjugated or biotinylated mouse 
anti-rat) for 1 h, followed by another washing step and subsequent incubation with 
Streptavidin Texas Red and/or Hoechst dye (to counterstain nuclear DNA). After a 
final washing step, the coverslips were mounted on glass slides with Histogel. The 
mounted cells were analysed using an inverse fluorescence/light microscope. 
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3.2.3.4 Reporter gene analysis 
 
For luciferase reporter assays, 293 cells were split into 12-well plates the day before 
transfection. All plasmids were transiently transfected using the Effectene 
Transfection Reagent (Qiagen) according to the manufacterer’s instructions. In all 
experiments, total amounts of transfected DNA were equalized between wells using 
empty pCR3. One day post transfection, cells were starved in DMEM, containing 1% 
fetal calf serum (plus TPA+Ionomycin [500 ng/ml+1 µM], IFN [500 U/ml] or forskolin 
[30 µM] if used as positive control), for another 24 h. After 48 h cells were harvested 
by flushing them off the the plates with 700 µl of cold PBS, transfered to a tube and 
centrifuged at 2000 rpm for 2 min (4°C, cooled microcentrifuge). Supernatants were 
discarded and luciferase activity was determined by using a commercial luciferase 
assay system (Promega) and a tube luminometer (Berthold) according to the 
manufacterer’s instructions. 
 
 
3.2.4 Protein techniques 
 
3.2.4.1 Cellular fractionation 
 
For particular fractionation, stimulated BCBL-1 cells and transfected 293 cells were 
washed twice with PBS and resuspended in hypotonic lysisbuffer (10 mM Hepes, 10 
mM KCl, 10 mM MgCl2, 0.5 mM EDTA with 1 mM PMSF and 2 mM Pefablock) 
(according Nagel et al., 1998). After an incubation of 10 min on ice, cells were 
sheared by passing through a 26 gauge needle. To separate nuclei, lysates were 
centrifuged 10 min at 4°C and 110 g, the pellets were washed three times with F-
actin buffer (10 mM HEPES pH 7.5, 0.5 mM ATP, 0.5 mM dithiothreitol, 20µM MgCl2, 
15% Glycerol) and resuspended in TE buffer (10 mM Tris, 1 mM EDTA pH 8). The 
postnuclear supernatant was ultracentifuged for 1 h at 4°C and 40,000 rpm and 
cytosolic supernatants were collected. The pellets were resuspended and washed 
with hypotonic lysis buffer and centrifuged for 10 min at 4°C and 14000 rpm. The 
resulting pellet was resuspended in hypotonic lysisbuffer containing 1% (vol/vol) 
Nonidet P-40, incubated on ice for 10 min and centrifuged again. Supernatants 
representing the detergent-soluble membrane fraction were collected, pellets 
representing the unsoluble fraction were resuspended in 2xSDS protein sample 
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buffer (10 % Glycerol, 0.2 % bromophenol blue, 4 % SDS, 4 % 2-mercaptoethanol, 
50 mM Tris pH 6.8). Fractions were directly analysed by SDS-PAGE or stored at -
20°C. 
 
 
3.2.4.2 Co-immunoprecipitation  
 
Co-immunoprecipitation was performed using the plasmids pGBKT7 and pGADT7 
with T7 promoter and recombinant vaccinia virus vT7 expressing the T7 RNA 
polymerase. 293 cells were cultured on 10 cm dishes and infected with vTF-7 at a 
MOI of 10 in serum-free medium. 1,5 h after infection, cells were transfected with 10 
µg of each of the two expression plasmids by calcium phosphate transfection. 
Expression was controlled using a GFP plasmid under the control of a T7 promoter 
(pTIT-GFP). After 24 h, cells were lysed by incubation in 1 ml of NP-40 lysis-buffer 
(1% NP-40, 140 mM NaCl, 5 mM MgCl2, 20 mM Tris pH 7,6, 1 mM PMSF) for 30 min 
on ice. Lysates were centrifuged for 10 min at 20,500 g and 4°C to remove 
unsolubilized material and precleared with 50 µl of preequilibrated protein G-
Sepharose. Subsequently, proteins were precipitated from the supernatant by adding 
200 µl hybridoma supernatant of the specific anti-DR monoclonal antibodies (mab) 
and 50 µl of protein G-Sepharose beads and incubating in an overhead mixer o/n at 
4°C. Beads were washed three times with ice-cold NP-40 buffer. Co-
immunoprecipitations, cellular subfractions and total cell lysates of BCBL-1 and 
transfected 293 cells were resuspended in 2xSDS protein sample buffer. Cellular 
subfractions and total cell lysates were additionally sonicated for 30 s. Samples were 
boiled for 5 min and directly analysed by SDS-PAGE or stored at –20°C. For the 
equilibration of protein G-Sepharose, 1.5 g were washed 3x and resuspended with 
NP-40 lysis-buffer to obtain a 50% slurry. 
 
 
3.2.4.3 Pull-down of recombinant SH3 domain proteins 
 
For pull-down experiments of recombinant GST-SH3 domain proteins (kindly 
provided by Dr. Stephan Feller, Oxford, UK) approximately 600 ml of n-butyrate 
induced BCBL-1 cells were lysed in 10 ml of NP-40 buffer. Subsequently the lysate 
was divided into 20x 500 µl aliquots and each aliquot was incubated in an overhead 
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mixer with 45 µl of protein G-Sepharose, 50 µl of kdr1-8D10 hybridoma supernatant 
and 10 µg recombinant protein each at 4°C o/n. Beads were washed three times with 
ice-cold NP-40 buffer and resuspended in 2xSDS protein sample buffer. After boiling 
for 5 min, samples were analysed by SDS-PAGE on 15% gels. Precipitated proteins 
were detected by Western blotting with an primary anti-GST antibody and a 
peroxidase-conjugated secondary antibody (see below). 
 
 
3.2.4.4 SDS PAGE 
 
Gel electrophoresis was performed with minigels using the Protean II system (Bio-
Rad) with 12 to 20%  gels (80 x 50 x 1 mm). The solution for generating the 
separation gel was mixed and after pouring, the gel was overlaid with isopropanol. 
After polymerization the isopropanol was sucked of the gel. The stacking gel solution 
was poured on top of the separation gel and a comb was fixed. After polymerization 
the glass plates containing the gel were assembled in the gel electrophoresis 
apparatus. Samples or pellets from immunoprecipitation were resuspended in the 
appropriate amount of 2xSDS protein sample buffer and heated for 5 min to 95°C. 
After cooling to RT the samples were centrifuged for 2 min at 14000 rpm 
(microcentrifuge) and loaded on the gel together with a protein standard. Separation 
was performed at 150 V constant current for 1-2 h. 
 
Separation Gel :       12%___    15%___    20%___                         
Acrylamide/ Bisacrylamide (37.5:1)    2 ml          2.5 ml       3.33 ml 
1.5 M Tris pH 8.8       1.25 ml     1.25 ml     1.25 ml  
10 % SDS        50 µl         50 µl         50 µl 
H2O         1.675 ml   1.175 ml   0.343 ml 
10 % APS        20 µl         25 µl         25 µl 
TEMED        2.5 µl        2.5 µl        2.5 µl 
 
 
 
 
 
 
                                                                                                  Material and Methods   
 
 41
Stacking gel:       5%____ 
Acrylamide/ Bisacrylamide (37.5:1)    1.35 ml 
0.5 M Tris pH 6.8       0.625 ml 
10 % SDS        25 µl 
H2O         1.53 ml 
10 % APS        12.5 µl 
TEMED        2.5 µl 
 
Electrophoresis buffer (10 x):    50 mM Tris 
384 mM glycine 
0.1% SDS  
 
 
3.2.4.5 Western blotting 
 
Proteins were blotted on nitrocellulose membranes using the Protean II system (Bio-
Rad). A piece of nitrocellulose membrane and two pieces of filter paper and two 
sponges of the same size as the gel were soaked with transfer buffer. A sponge, a 
piece of filter paper, the nitrocellulose membrane, the gel, another piece of filter 
paper and again a sponge were packed. Subsequently, air bubbles were removed by 
rolling a test tube over the sponge and the package was clamped into the transfer 
tank with the nitrocellulose facing the anode. Blotting was performed with 100 V 
constant for 1 h. Proteins were detected after 2 min incubation in Ponceau staining 
solution. The membranes were labeled with a pen and was washed several times 
with H2O to remove the Ponceau staining solution. Unspecific binding sites were 
blocked by incubation in TBST (TBS, 0.05% Tween 20), 5% skim milk powder, 
0.02% NaN3 either 1 h at RT or o/n at 4°C. Then incubation with the first antibody 
was performed in 5-10 ml TBST (used also in the following washing and incubation 
steps) at 4°C o/n. After five washing steps of 15 min with approximately 200 ml buffer 
each, incubation with the secondary antibody coupled to peroxidase was performed 
in 15 ml buffer at RT for 1 h followed by washing 5x 10 min in 200 ml buffer.The 
blotted proteins were detected using the ECL Western blotting detection system 
(Amersham-Pharmacia) according to the manufacturer’s instructions. The membrane 
was exposed to BIOMAX-MR autoradiography films for different time periods and 
films wre developed using an automatic film developing machine. 
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Transfer buffer (1l):     Ponceau solution (100 ml):  
Tris base 5.8 g      Ponceau S 0.5 g 
Glycine 2.9 g      Glacial acetic acid 1 ml 
SDS 0.37 g       H2O 98.5 ml 
Methanol 200 ml 
H2O to 1l 
 
 
3.2.4.6 Purification of recombinant DR2 and DR1 GST-tagged fusion proteins 
 
To generate monoclonal antibodies, DR1 and DR2 repeats were expressed as GST-
fusion proteins. Therefore 100 ml of o/n cultures of BL 21 containing the pGEX-DR2 
and the pGEX-DR1 construct, respectively, were diluted with 500 ml prewarmed 
selection medium (LB with 100 µg/ml ampicillin) to an OD600nm of 0.1 and grown at 
37°C to an OD600nm of 0.5. Subsequently,  500 ml of the cultures were  induced with 
an IPTG concentration of 1 mM, followed by a 3 h incubation at 37°C. After 
incubation the cultured bacteria were pelleted by centrifugation at 4000 g for 20 min 
and resuspended in 30 ml PBS containing 1 mM PMSF and 2 mM Pefablock  at 4°C, 
before being sonicated 3x for 20 s (output control level 7, 100 %) with a Branson 
Sonifier 450. 1 ml of 10 % Triton X-100 was added, solutions were shaken for 30 min 
at 4°C and centrifuged for 10 min at 4000 g following passage of the supernatants 
through a 0.45 µm filter. Cell extracts were combined with 2 ml of 50 % slurry of the 
Glutathione-agarose resin in PBS for each 100 ml of bacterial culture used to make 
the protein extract and the mixture was shaken for 1 h at 4°C. Beads were 
centrifuged down at 500 g for 5 min at 4°C and washed 3x with 10 bed volumes of 
PBS containing 1 % Triton X-100. GST-fusion proteins were eluted from the washed 
beads by adding one bed volume of Glutathione elution buffer (10 mM reduced 
Glutathione, 50 mM Tris-HCl pH 8.0) to the pellet. After incubation with gentle 
agitation for 10 min at RT beads were centrifuged again and the supernatants (which 
contain the eluted fusion proteins) were transfered to a fresh tube (this was repeated 
2 times). Eluted fractions were analysed by SDS-PAGE on 12 % gels.  
 
 
 
                                                                                                  Material and Methods   
 
 43
3.2.4.7 Purification of recombinant His-tagged DR2 fusion protein 
 
20 ml of an o/n culture of BL21 RIL containing the pET 15b DR2 construct were 
added to 3 l of prewarmed selection medium (LB with 100 µg/ml ampicillin, 
chloramphenicole 100 µg/ml) and grown at 37°C to an OD600nm of 0.4-0.5. 3ml 1 M 
IPTG was added to the medium followed by a 4 h incubation at 30°h. Bacteria were 
pelleted by centrifugation at 4000 g for 20 min and resuspended in 3 ml/g buffer 1 
(200 mM NaCl, 3 mM imidazole, 20 mM Tris , pH 7. 6 including 1 mM PMSF) at 4°C. 
Subsequently the resuspension was sonicated 3x for 2 min (output control level 6) on 
ice water and centrifuged at 10000 g for 30 min and 4°C. The supernatant was used 
as mentioned below and a sample of the pellet was resuspended in 10 M urea and 
stored for SDS-PAGE analysis. Approximately 2-3 ml Ni-agarose beads were 
washed in 10 ml buffer 5 (200 mM NaCl, 300 mM imidazole, 20 mM Tris , pH 7. 6 
including 1 mM PMSF), the suspension was loaded to a column and the beads were 
equilibrated with 6 bed volumes of buffer 1. The supernatant of the sonicated 
bacterial solution containing the soluble fusion protein was loaded on the column and 
washed with 4 bed volumes of buffer 1. Hereafter the HisTag-fusion protein was 
eluted with each 2x 5 ml buffer 2, 3, 4 (composition similar as buffer 1 but with 50 
mM, 100 mM, 150 mM imidazole, respectively) and 5. Eluted fractions and samples 
of solution steps were analysed by SDS-PAGE on 12% gels. 
 
 
3.2.4.8 Coomassie blue staining 
 
For Coomassie blue staining of proteins, SDS-PAGE gels were incubated in 
Coomassie blue staining solution for 1-12 h and destained with 30% methanol/10% 
acetic acid by changing the destaining solution until the desired protein staining was 
visible.  
 
Coomassie blue staining solution:  0.25% Coomassie brilliant blue R-250 
45% methanol  
10% acetic acid 
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3.2.4.9 Generation of rat monoclonal antibodies 
 
Rat monoclonal antibodies were generated by Elisabeth Kremmer, GSF, Munich, 
Germany (Kremmer et al., 1995). Lou/C rats were immunized 3x with 50 µg DR1-
GST-fusion protein at a time in intervals of three weeks. The first injection was done 
with complete Freund’s adjuvant, the second with incomplete Freund’s adjuvant both 
intraperitoneally and subcutaneously and the third without adjuvant intraperitoneally. 
For DR2 the procedure was similarly as described above, performing the first 
immunization with DR2-GST-fusion protein. However, for the second and third 
injection DR2-HisTag-fusion protein was used. Fusion of rat immune spleen cells 
with the myeloma cell line P3X63Ag8.653 was performed following the protocol of 
Köhler and Milstein 3 days after the final boost (Kohler and Milstein, 1992). 
Supernatants from hybridoma cells were tested by Western blotting for the presence 
of anti-DR2 and anti-DR1 antibodies, respectively. SDS-PAGE gels with lysates of 
induced BCBL-1 cells were blotted onto nitrocellulose, and unspecific binding sites 
were blocked by incubation in TBST (TBS, 0.05% Tween 20), 5% skim milk powder, 
0.02% NaN3 for 1 h at RT. Thereafter the membranes were cut into small strips and 
each strip was put into a separate slot of a multi-slot chamber (selfconstructed). The 
Hybridoma supernatants were added and incubated o/n at 4°C with constant shaking 
followed by 3x 15 min washing steps with TBST and incubation with an alkaline 
phosphatase-conjugated goat anti-rat antibody (1:1000 in TBST diluted). Finally, 
bound antibodies were detected using the Western Blue Stabilized Substrate for 
Alkaline Phosphatase (a mixture of BCIP and NBT in a proprietary stabilizing buffer, 
Promega) according to the manufacterer’s instructions. Hybridoma cells producing 
antibodies recognizing DR2 or DR1 repeats were subcloned at least twice by limiting 
dilution. The immunoglobulin-isotypes were determined by ELISA. 
 
 
3.2.5 Yeast culture 
 
3.2.5.1 Competent yeast cells 
 
To produce competent yeast cells, a preculture was prepared first. 10 ml YPD-
medium were inoculated with one colony of the yeast strain AH109 overnight at 
30°C. The following day, the preculture was added to 250 ml of fresh YPD-medium 
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and grown at 30°C until it reached an OD600 of 0.6. Cells were harvested in 50 ml 
Falcon tubes by centrifugation at 930 g for 5 min at 4°C. The supernatant was 
discarded and the cells were resuspended in 12.5 ml SBEG-solution each and 
subsequently pelleted another time. The resulting cell pellet was resuspended in 500 
l SBEG-Solution and parted into 100 l aliquots. The aliquots were shock-frozen in 
liquid nitrogen and stored at – 80°C. 
 
YPD medium (1 l): 
For liquid medium:        10 g Bacto yeast extract  
  20 g Bacto peptone 
  20 g Dextrose 
add H2O to 1 liter, autoclave 
For solid medium:     add 20 g agar before autoclaving 
 
SBEG-solution:          1 M Sorbitol 
  10 mM Bicine pH 8,35 sterile 
    3 % Ethylene glycol 
 
 
3.2.5.2 Transformation and test of protein interaction 
 
For transformation, a microlitertube with 100 l competent AH109 yeast cells was 
thawed quickly in a waterbath at 37°C. Subsequently 1 g of the used bait- 
(pGBKT7) and prey- (pGADT7) constructs was pipetted into the thawed yeast cells 
and mixed carefully with a pipet. 750 l PEG/Bicine-solution were added, the 
suspension was mixed again and the reaction was incubated at 30°C for 1 h, 
followed by incubation for 5 min at 45°C. The next step was to pellet the cells for 2 
min at 2700 g in a table centrifuge. The supernatant was removed by a pasteurpipet 
and the pellet was resuspended in 1ml NB-buffer. Again cells were pelleted, as 
described above, but only 800 l of the supernatant were removed. 
 
PEG/Bicine-Lösung:     40 % PEG 1000 
         200 mM Bicine, pH 8,35, sterile 
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NB-Puffer:         0,15 M NaCl 
          10 mM Bicine pH 8,35, sterile 
 
The pellet was resuspended in the remaining 200 l supernatant and plated on SD/-
Leu/-Trp plates, consisting of SD Base medium (+ 2% Agar) containing different 
formulation of dropout (DO) supplement (amino acid mixture, lacking the indicated 
amino acids). In pGBKT7, which has a Trp1 nutricion marker, the bait gene is 
expressed as a fusion to the GAL4 DNA-binding domain, while the prey gene is 
expressed in pGADT7 (Leu2 nutricion marker) as a fusion to the GAL4 activation 
domain. For detection of protein-protein interactions of the expressed constructs, 
colonies were replated on SD/-Ade/-His/-Leu/-Trp/X--gal, and positive clones were 
detected by growth and by -galactosidase activity according to the Matchmaker 
Gal4 Two-Hybrid System 3 User Manual (Clontech, 1999). 
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4 Results 
 
4.1 Expression of the DR2 and DR1 repeat region as GST-fusion 
proteins in E. coli 
 
For examinations concerning the biochemistry of proteins, monoclonal antibodies are 
indispensable molecular detection tools used in a vast number of techniques. To start 
the investigations on the kaposin protein isoforms, the first step was to rise mabs 
against the repeat regions of the K12 locus, since only mabs against the c-terminus 
of the ORF K12 (kaposin A) were present at the beginning of this study. 
For this purpose the DR2 and the DR1 repeat regions were expressed in E.coli as 
Glutathione-S-Transferase (GST)-fusion proteins. After induction with IPTG, a 
significant part of the bacterial proteins was contributed by the DR-GST-fusion 
protein (shown for DR1, Fig. 7A). Both of the recombinant proteins were found to be 
soluble in sufficient amounts and were purified by affinity chromatography using 
Glutathione-agarose resin (Fig. 7B). Although the purification was not complete, the 
proteins were sufficiently pure for immunization of Lou/C rats. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7: Expression and purification of DR-GST-fusion proteins 
(A) Expression of GST-DR1 in E. coli. The DNA encoding DR1 repeats was cloned into the bacterial 
expression vector pGEX-4T-1 and the GST-fusion protein was expressed as described in Materials 
and Methods (the same procedure was carried out for DR2 repeats, data not shown). Supernatants of 
E. coli cell lysates (after sonication) from 0-2h IPTG induced cultures were analysed by SDS-PAGE 
(lanes 1-3, pGEX-4T-1 transformed control culture; lanes 4-6, pGEX-DR1 transformed culture). 
Specific bands are indicated by arrows. (B) Elution of recombinant DR1- and DR2-GST-fusion 
proteins. Recombinant GST-fusion proteins were eluted from the Glutathione-agarose resin as 
described in Material and Methods and analysed by SDS-PAGE (lane 1, GST; lane 2, GST-DR1; lane 
3, GST-DR2). Specific bands are indicated by arrows. 
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4.2 Expression of the DR2 repeat region as a HisTag-fusion protein 
in E. coli 
 
An earlier attempt to boost the immunized rats with the recombinant GST-DR2-fusion 
protein was not successful. To eliminate the clones directed against the Tag 
sequence and also to enhance the specific immune response against DR2, the boost 
of the GST-DR2 immunized rats in this approach was performed with a DR2-HisTag-
fusion protein. Thus the DR2 repeat region was expressed as a recombinant 
Histidine-tagged protein in E. coli. The transformed bacteria expressed the 
approximately 20 kd DR2-fusion-protein after IPTG induction. After lysis of the 
bacteria, it was found in the supernatant in reasonable amounts. Subsequently, the 
recombinant DR2-His-Tag-fusion protein was purified from the lysis supernatant via 
affinity chromatography using a Ni-agarose beads column (Fig. 8). An adequate 
purity level was reached, and the recombinant protein of fraction 8 (lane 12) was 
used for the boost.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8: Expression and purification of DR2-HisTag-fusion protein 
(A) Expression of DR2-HisTag-fusion protein in E. coli. The DNA encoding DR2 repeats was cloned 
into the bacterial expression vector pET-15b and the DR2-HisTag-fusion protein was expressed as 
described in Materials and Methods. Samples of the resuspended pellet (p) as well as the supernatant 
(s) obtained after sonication were analysed by SDS-PAGE. Specific bands are indicated by arrows. 
(B) Elution of DR2-HisTag-fusion protein. Recombinant DR2-HisTag-fusion protein was eluted from 
the Ni-agarose column as described in Material and Methods. Samples of  the resuspended pellet 
(lane 1) and the supernatant (lane 2) obtained after sonication, flow through (lane 3), washing steps 
(lane 4, 3 mM imidazole buffer; lane 5 and 6, 50 mM imidazole buffer) and eluted fractions (lanes 7-
12, each 2x eluted with 50 mM, 100 mM and 150 mM imidazole buffer, respectively) were analysed by 
SDS-PAGE. Specific bands are indicated by arrows. 
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4.3 Generation of monoclonal antibodies against DR2 and DR1 
repeat regions 
 
To generate monoclonal rat antibodies, the purified recombinant DR proteins were 
used for immunization of Lou/C rats as described in Material and Methods (done in 
cooperation with Elisabeth Kremmer, GSF, Munich, Germany). The hybridoma 
supernatants containing the rat monoclonal antibodies were tested by Western Blot 
analysis using total cell lysate of the n-butyrate induced, HHV-8 positive cell line 
BCBL-1. Antibodies in several of the tested hybridoma supernatants detected bands 
that correlated to the predicted sizes of the respective kaposin isoforms (shown for 
DR2 only, Fig. 9A and see also below). After the subcloning of the hybridoma cells, 
only clones 4C6 and 6H8 (recognizing DR2) as well as clones 3C12 and 8D10 
(recognizing DR1) produced still antibodies that were tested positive in different 
immunoassays. These antibodies showed activity in Western Blots, 
immunofluorescence and immunoprecipitation (Fig. 9B and Table 1, data not shown) 
and were used in the following experiments. The isotypes of antibodies of clones 
kdr1-4C6, kdr2-6H8 and kdr1-8D10 were determined to be isotype IgG1, clone 3C12 
was determined as isotype IgG2a.  
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Fig. 9: Test of hybridoma supernatants by Western Blot analysis 
(A) Test of hybridoma supernatants of several clones before subcloning (e.g. anti-DR2 ). SDS-PAGE 
gels of induced BCBL-1 lysates were blotted onto nitrocellulose. Subsequently, the membranes were 
cut into small strips. Each strip was incubated with a different hybridoma supernatant and 
subsequently developed as described in Material and Methods. Specific bands are indicated by 
arrows. (B) Test of positive hybridoma supernatants of anti-DR2 and anti-DR1 clones after subcloning. 
Experiments were performed similarly as described above. Specific bands are indicated by arrows. 
 
 
 
Table 1: Test of monoclonal antibodies against DR2 and DR1 repeat regions by Western blotting 
(WB), immunofluorescence (IF) and immunoprecipitation (IP). 
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4.4 A variety of kaposin isoforms is generated by initiation at 
multiple start codons 
 
Kaposin A, the product of the originally identified KSHV ORF K12, is expressed by 
the majority of unstimulated PEL cells latently infected with KSHV. In contrast, 
antibodies against DR2 and DR1 recognize only a small number of unstimulated PEL 
cells, which considerably increases after stimulation with n-butyrate or phorbol ester, 
indicating that kaposin isoforms containing these repeats are expressed rather during 
the lytic phase (data not shown). To biochemically characterize the expression 
pattern of the kaposin protein isoforms in KSHV-infected cells, lysates of the n-
butyrate-induced PEL cell line BCBL-1 were analysed by SDS-PAGE and Western 
blot analysis using monoclonal antibodies against single protein domains (Fig. 10). 
Using antibodies against DR2, two bands were detected. The faint band of 
approximately 54 kd correlates with the size of the translational product initiating from 
a CUG codon 5’ of the DR2 repeats in frame 1 and represents the kaposin C isoform. 
The strongly predominant second band of about 48 kd representing the kaposin B 
isoform correlates with the size of a translation product that initiates at the first CUG 
codon in reading frame 2. As presumed, these two bands representing kaposin B 
and C were also detected by an antibody against DR1. Additionally, a whole array of 
bands ranging from approximately 38 to 24 kd (after longer exposure down to 18 kd) 
were detected, which represents isoforms that initiate from CUGs within each DR1 
repeat in all three reading frames. Whereas isoforms expressed from reading frames 
2 and 3 cease at the end of the DR1 repeats due to stop codons, isoforms expressed 
from reading frame 1 continue to the stop codon of ORF K12 and are thus 
approximately 6 kd larger in size (Fig. 11). To discriminate these isoforms, the terms 
kaposin D for isoforms consisting of DR1 repeats and ORF K12 (reading frame 1) 
and kaposin E for isoforms consisting only of DR1 repeats (frame 2 and 3) were 
introduced. Since the CUG sequence context is identical in all three reading frames, 
initiation should occur at an equal rate and therefore kaposin E is expected to be two 
times more abundant than kaposin D. The antibody against K12 detected the kaposin 
A, C and D isoforms, but not kaposin B and E. The protein band at 12 kd rather 
represents a dimeric form of kaposin A than a small form of kaposin D, since it was 
not detected by the anti-DR1 antibody. A similar expression pattern was observed in 
293 cells transfected with a plasmid expressing a XhoII/Nhe1 fragment containing the
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whole genomic region under control of a CMV promoter (Fig. 12, Kaposin C). In 
summary, the Western blot analyses indicate that a variety of different kaposin 
isoforms is produced from one single transcript in PEL cells, indicating that the CUGs 
start codons at the 5’ end of DR2 and in DR1, as well as the AUG at the 5’ end of 
K12 are used by a leaky scanning mechanism.  
 
 
 
 
Fig. 11: Kaposin is expressed from multiple translational initiation sites in PEL cells 
Schematic diagram of the kaposin protein isoforms expressed from different CUG and AUG start 
codons on the viral transcript. Kaposin protein isoforms are sorted according to the position of their 
start codon with the upmost isoform expressed from the first start codon on the transcript. Kaposin 
isoforms are termed according to the domains they contain: A … K12; B … DR2 + DR1; C ... DR2 + 
DR1 + K12; D … DR1 + K12; E … DR1. Stop codons are indicated by asterisks. Kaposin transcripts 
have been reported to be spliced 5’ of DR2 in some cell lines (Li et al., 2002). Square boxes with 
triangles mark single DR2 or DR1 repeats.  
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4.5 Kaposin isoforms localize to different cellular compartments 
 
To evaluate the localization of the kaposin isoforms within the cell, constructs 
expressing single or few kaposin isoforms were generated and tested by fractionation 
(Fig. 12) and immunofluorescence after transfection (Fig. 13). Cellular subfractions of 
transiently transfected 293 cells were analysed by Western blot analysis with mabs 
against each of the three domains (Fig. 12). As reported previously, kaposin A was 
detected nearly exclusively in the unsoluble membrane fraction (m2) in the 
fractionation experiment (Kliche et al., 2001; Muralidhar et al., 1998; Muralidhar et al., 
2000). Kaposin B was predominantly located in the nuclear fraction and in the 
unsoluble membrane fraction (presumably because of a contamination with nucleic 
components). In accordance with the K12 transmembrane domain, the kaposin C 
and D isoforms were found exclusively in the unsoluble membrane fraction (m2). In 
contrast, kaposin E was detected solely in the cytosolic fraction and thus represents 
a cytosolic member of the kaposin protein family. The difference in size between 
kaposin D and kaposin E corresponds to the 6 kd size of ORF K12. Due to the 
occurrence of alternative start codons in DR1, kaposin E is co-expressed with 
kaposin B, C and D, and kaposin B, D and E with kaposin C. The localization in 
distinct cellular compartments was confirmed by immunofluorescence in transfected 
Hela cells (Fig. 13). Kaposin A, C and D were located in vesicular structures and at 
the plasma membrane, kaposin B in the nucleus and kaposin E in the cytosol.  
The kaposin D construct used in these experiments still contained the DR2 repeat 
region but without the upstream CUGs, since it was not expressed if DR2 was 
completely deleted. Thus, kaposin B and C expression was reduced but not 
completely abolished and some nuclear (kaposin B) and membrane-associated 
(kaposin C) localization was still detected with the DR2 antibody. 
 
 
Fig. 12: Cellular fractionation reveals a distinct subcellular localization pattern of different 
kaposin isoforms in transfected 293 cells 
Plasmid constructs expressing distinct kaposin isoforms (pCR3kapB, pBCBL-1, pCR3kapD, 
pCR3kapE) were transiently transfected into 293 cells and subcellular fractions were analysed by 
Western blot analysis using antibodies against DR2, DR1 and K12. Kaposin A was expressed by a 
recombinant vaccinia virus. Subcellular fractions (c: cytosolic fraction; m1: detergent-soluble 
membrane fraction; n: nuclear fraction; m2: detergent-unsoluble membrane fraction) were separated 
by SDS-PAGE on 12% gels (kaposin A 20%), blotted and stained with anti-DR2, anti-DR1 or anti-K12 
mabs. The scheme indicates the isoforms expressed by each construct. The asterisks indicate the 
corresponding band(s) for each isoform. The purity of the nuclear, cytosolic and detergent-soluble 
membrane fractions was controlled by the marker proteins lamin B, 14-3-3 and calnexin, respectively. 
The kaposin D construct used in this experiment still contained the DR2 repeat region but without 
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CUGs, since it was not expressed if DR2 was completely deleted. This is the reason why some 
material is still detected in the m1, m2 and n fractions recognized with the anti-DR2 mab.  
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To confirm subcellular distribution in naturally infected PEL cells, n-butyrate induced 
KSHV+ BCBL-1 cells were analysed by double immunfluorescence staining and 
cellular fractionation. 
For the double immunofluorescence staining, the induced BCBL-1 cells were co-
stained with different combinations of antibodies (Fig. 14). Detection with an anti-DR2 
mab showed a predominant nuclear, as well as some vesicular staining. The anti-
DR1 mab showed also nuclear staining but recognized additionally cytoplasmatic 
structures. The anti-kaposin A mab detected extended membrane-associated 
staining (Fig. 14 middle panel) and also vesicular structures, which are located in the 
perinuclear area of the cell (Fig. 14 lower panel). In the merge of anti-DR2 and anti-
DR1, the localization of the kaposin isoforms B (yellow nuclear staining) and C 
(yellow vesicular staining) can be distinguished from the isoforms D and E (green 
cytoplasmatic staining) (Fig. 14 upper panel). 
In parallel to the immunofluorescence analysis, cellular fractionation of induced 
BCBL-1 cells was performed (Fig. 15). In principle, this experiment displays a two-
dimensional resolution of the Western blot analysis of total cell lysate shown before 
(see Fig. 10). The evaluation of the Western blot analysis of the subcellular fractions 
showed similar results as seen with transfected cells (compare Fig. 12): Kaposin B 
was predominantly located in the nuclear subfraction, wheras kaposin C was found 
exclusively in the detergent unsoluble membrane fraction. The likewise membrane-
associated kaposin D isoforms differed around 6kd (the size of the ORF K12) from 
the cytosolic kaposin E isoforms (Fig. 15 middle) and kaposin A was again shown to 
be located in the detergent unsoluble membrane fraction. 
In summary, both experiments confirmed that in lytic reactivated BCBL-1 cells all 
kaposin isoforms are similarly localized as observed by expression in transiently 
transfected cells. 
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Fig. 14: Immunofluorescence analysis in BCBL-1 PEL cells 
Localization of different kaposin isoforms in KSHV-infected cells. N-butyrate induced BCBL-1 cells 
were fixed with methanol and co-stained with either kdr2-4C6 (anti-DR2) and kdr1-3C12 (anti-DR1) 
(top), kdr1-8D10 (anti-DR1) and kap-4F11 (anti-K12) (middle) or kdr2-4C6 and kap-4F11(bottom). 
Subsequently, cells were stained with FITC- and Texas red-conjugated secondary reagents. 
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4.6 Kaposin is a transcriptional activator 
 
It was previously found by luciferase reporter gene assays that kaposin A induces the 
TRE promoter element containing an AP-1 binding site (Kliche et al., 2001). Thus, in 
this study it was tested whether kaposin isoforms B, C, D and E, which are 
expressed during the lytic phase, are also transcriptional activators. A variety of 
different promoters containing binding sites for AP-1, CRE, NF-B and p53, as well 
as promoters with SRE and ISRE elements, HIV-1 LTR and cellular IL-6 and VEGF 
promoters were screened with a genomic construct expressing all kaposin isoforms 
(Fig. 16) also by performing by luciferase reporter gene assays. Kaposin activated 
AP-1 to a similar level as phorbol ester/ionomycin stimulation. Kaposin also slightly 
activated the interleukin-6 (IL-6) and VEGF-1 promoters, suggesting a putative role in 
the regulation of these cellular promoters. None of the other promoters was activated 
by kaposin considerably, outruling a general inductive effect. 
 
 
 
Fig. 16: Kaposin activates the AP-1 transcription factor and cellular promoters 
An expression plasmid expressing all kaposin isoforms was co-transfected into 293 cells with a variety 
of luciferase reporter plasmids with different binding sites or promoters: AP-1, CRE, NF-B, p53, SRE, 
ISRE, HIV-1 LTR, IL-6 promoter, VEGF-1 promoter. As a negative control, cells were co-transfected 
with pCR3. As a positive control, cells were either co-transfected with plasmids expressing either 
RasV12, p53 or HIV-1 Tat, or stimulated with either IFN, forskolin or phorbol ester (TPA)/ionomycin 
(Iono). Data represent mean  standard deviation of two independent experiments performed in 
triplicates.  
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4.7 DR2 repeats contain a nuclear localization signal 
 
Since the kaposin B isoform containing the DR2 repeat region localizes to the 
nucleus (Fig. 12-15), it was hypothesized that DR2 contains a nuclear localization 
signal (NLS). Although the DR2 peptide sequence shows no canonical NLS, there is 
a high abundance of basic and hydrophilic amino acids, which are known to be 
present in a classical NLS (Fig. 17). To test if the NLS was in fact located within the 
DR2 repeats, kaposin B and the DR2 or DR1 repeat regions were expressed as GFP 
fusion proteins in Hela cells. Immunofluorescence analysis of pEGFP-kapB and 
pEGFP-DR2 transfected cells indicated a complete translocation of the GFP from the 
cytosol into the nucleus, whereas transfection with pEGFP-DR1 resulted in a similar 
cellular distribution of GFP as seen in control cells, transfected with the empty 
pEGFP vector (Fig. 18). These results confirmed that the functional NLS, responsible 
for the nuclear shift of the kaposin B isoform, is in fact localized within the DR2 
repeat region. 
 
Fig. 17: High abundance of basic amino acids in the DR2 repeat sequence 
23-amino acid sequence of one DR2 repeat, shown in single letter code. Basic arginine residues are 
red underlayed. 
 
 
 
 
 
 
 
 
 
 
 
 
HPRNPARRTPGTRRGAPQEPGAA
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Fig. 18: The DR2 repeat region contains a functional nuclear localization signal 
Hela cells were transiently transfected by calcium phosphate coprecipitation with either a pEGFP-C1 
control plasmid or pEGFP-DR2, pEGFP-DR1 and pEGFP-kapB fusion constructs.  
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4.8 DR2 and DR1 repeat regions interact with each other 
 
Surprisingly, when GFP fusion proteins of DR2 and DR1 were co-expressed in Hela 
cells, only a nuclear GFP staining was observed (Fig. 19). The cytosolic GFP-DR1 
was relocalized to the nucleus by the NLS containing GFP-DR2, suggesting a direct 
interaction between the two repeats.  
 
 
 
Fig. 19: Nuclear relocalization of DR1 by DR2 
Hela cells were transiently transfected with pEGFP-DR2 and pEGFP-DR1 by calcium phosphate 
coprecipitation and subsequently analysed by immunofluorescence. 
 
 
To further examine this interaction between both repeats, co-immunoprecipitation 
experiments were carried out. Kaposin B, DR2 and DR1 repeat regions were co-
expressed in 293 cells as Myc- or HA-tagged proteins under the control of a T7 
promoter using recombinant vaccinia virus which expresses the T7 RNA polymerase 
(Fuerst et al., 1986). Cell lysates were precipitated with antibodies directed against 
either DR2 and DR1 or HA and Myc tags. Kaposin B was found to interact with itself. 
DR1 was found to interact with itself as well as with DR2, whereas DR2 did not 
interact with DR2 (Fig. 20). These experiments support the results of the 
immunofluorescence experiment. 
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Fig. 20: DR2 and DR1 repeat regions directly interact with each other  
Co-immunoprecipitation of kaposin B, DR2 and DR1 repeat regions. The antibodies used for the 
immunoprecipitation are indicated below the gels, the antibodies used for detection by Western blot 
above the gels and the constructs transfected on the left side of the gels. Kaposin B and the DR2 and 
DR1 repeat regions were expressed in 293 cells using pGBKT7 and pGADT7 plasmids, in which they 
are expressed as Myc- or HA-tagged proteins under T7 promoter control. Co-immunoprecipitation was 
carried out either with anti Myc- or anti HA-Tag mabs or specific mabs against DR2 and DR1. 
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Subsequently, the DR2 and DR1 repeat regions were tested in luciferase reporter 
gene assays for AP-1. Whereas isolated DR2 and DR1 repeat regions induced AP-1 
only at backround levels, interestingly, co-expression of both molecules induced AP-
1 approximately 7-fold compared to the negative control, further supporting a 
functional interaction between the two repeat regions (Fig. 21).  
 
 
Fig. 21: Induction of AP-1 by interacting DR2 and DR1 repeats  
Luciferase reporter plasmid pRTU14 (80ng), which consists of a luciferase reporter gene under the 
control of a minimal promoter and four TREs, was transfected into 293 cells together with 160 ng DNA 
of either pRK5c-mycRasV12, pEGFP-kapB, pEGFP-DR2, pEGFP-DR1 or pEGFP-DR2 and pEGFP-
DR1. Negative control cells were transfected with pCR3. The control reporter plasmid pRTU1 lacking 
the four TRE sites showed minimal basal activity only (data not shown). Data represent mean  
standard deviation of three independent experiments performed in triplicates.  
 
 
In this assay also kaposin B was included. The level of th AP-1 induction caused by 
kaposin B reached up to 12-fold, comparable with the positive control, the 
constitutively active mutant RasV12. This result indicates that the kaposin B isoform 
is responsible for the inductive effect observed with the genomic K12 construct (see 
Fig. 16). 
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4.9 Both DR2 and DR1 repeats are mandatory for AP-1 induction 
 
To clarify if there was a correlation between AP-1 induction and nuclear localization 
of kaposin B, a construct was generated which translocates the DR1 repeats into the 
nucleus by a SV-40 NLS. The nuclear targeting of DR1-NLS was confirmed by 
immunofluorescence (Fig. 22). 
 
 
 
 
Fig. 22: DR1 repeats with a SV-40 NLS are localized in the nucleus  
Immunofluorescence analysis of pEGFP-DR2 and pEGFP-DR1-NLS in transiently transfected Hela 
cells. 
 
 
This construct was subsequently used in AP-1 luciferase gene reporter assays. 
Remarkably, co-expression of DR2 and DR1-NLS led to a similar activation as 
observed with kaposin B (Fig. 23). In contrast, DR2 and DR1-NLS were not able to 
induce AP-1 notably if expressed alone. This finding suggests that DR2 has a dual 
function and works not only as a targeting but also as a coactivator domain. 
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Fig. 23: Nuclear localization of both DR2 and DR1 repeat regions is mandatory for AP-1 
induction 
Co-expression of pEGFP-DR2 and pEGFP-DR1-NLS induces AP-1 to a similar extent as kaposin B. 
Experiments were performed similarly as described above. Data represent mean  standard deviation 
of two independent experiments performed in triplicates.  
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4.10 Co-expression of different kaposin protein isoforms influences 
their functional activity 
 
Since several kaposin isoforms are co-expressed and may bind to each other in 
BCBL-1 cells during the lytic phase, it was hypothesized that different isoforms 
functionally influence each other. To address this, individual isoforms were co-
transfected into 293 cells and AP-1 luciferase assays perfomed (Fig. 24). 
Remarkably, kaposin B-induced AP-1 activation was markedly increased by co-
transfection of kaposin E. However, this effect was counteracted by the expression of 
kaposin D. A similar inhibitory result was also achieved if kaposin B was co-
expressed with kaposin D. Kaposin D and E isoforms alone, as well as in 
combination, were not able to induce AP-1. Thus, our data suggest that by 
bidirectional targeting of kaposin E, which contains the coactivator domain, into 
distinct cellular compartments through either kaposin B or D, AP-1 induction can be 
either increased or decreased. 
 
 
Fig. 24: Co-expression of different kaposin isoforms modulates their functional activity 
Kaposin E and D modulate AP-1 activation induced by kaposin B in luciferase reporter assays. Equal 
amounts of the control vector, pRK5c-mycRasV12, pCR3kapB, pCR3kapD and pCR3kapE were 
transfected into 293 cells together with the AP-1 luciferase reporter plasmid pRTU-14. Similar protein 
amounts were used in the luciferase assays for each sample. Data represent mean  standard 
deviation of two independent experiments performed in triplicates. The kaposin D construct used in 
this experiment did not contain any DR2 repeats but a HA Tag with an AUG start codon.  
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4.11 Kaposin B contains proline-rich motifs and interacts with a 
variety of SH3 domain proteins 
 
Closer investigation of the repeat peptide sequences revealed that both DR2 and 
DR1 repeats are proline-rich and, in particular, that each repeat contains two PxxP-
motifs.  
 
 
 
 
 
 
Fig. 25: Amino acid sequence of the DR2 and DR1 repeat 
DR2 peptide sequence (top); DR1 peptide sequence (below). PxxP-motifs and proline-rich stretch are 
green underlayed. 
 
 
Since PxxP motifs are known targets for proteins containing Src homology 3 (SH3) 
domains, several interaction partners could be possible for both repeat regions (Ren 
et al., 1993). SH3 domains regulate protein localization, enzymatic activity and often 
participate in the assembly of multicomponent signaling complexes (Mayer and Eck, 
1995; Schlessinger, 1994). To test whether kaposin isoforms consisting of multiple of 
DR2 and/or DR1 repeats interact with such proteins, pull-down experiments were 
performed. Therefore different recombinant GST-SH3 domain proteins (provided by 
Dr. Stephan M. Feller, University of Oxford, Oxford, UK) were added each to NP-40-
lysates of induced BCBL-1 cells and precipitated with an anti-DR1 mab bound to 
protein G-Sepharose. Subsequent Western blot analysis showed indeed several SH3 
proteins as interaction targets, although the intensity of the interactions varied 
between the single domains (Fig. 26). 
Considering the high abundance of proline-rich motifs in kaposin, the binding to SH3 
domains is not surprising and the interactions seem to be more general than specific 
to a particular SH3 domain protein. Surprisingly, beside the n- and c-terminal SH3 
domains also the SH2 domain of the Grb2 adaptor protein (molecular structure: SH3-
SH2-SH3) was pulled down by kaposin, which can not be explained by interaction 
with known specific binding sites. Nevertheless, the interaction between kaposin B 
HPRNPARRTPGTRRGAPQEPGAA 
TWCPPPREPGALLPGNLVPSSPG 
DR2 
DR1 
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and Grb2 was confirmed by yeast two hybrid- and co-immunoprecipitation- 
experiments (Table 2 and Fig. 27). 
 
 
 
Fig. 26: Kaposin B interacts with different SH3 domain proteins 
In a pull-down experiment NP-40 lysates of n-butyrate induced KSHV infected BCBL-1 cells were 
mixed with approximately 10 µg of recombinant GST-fusion proteins or GST control. 
Immunoprecipitation against kaposin B was performed as indicated in Material and Methods. After 
electrophoresis, proteins were blotted onto nitrocellulose and detected by an anti-GST antibody. 
 
 
 
 
 
 
Table 2: Yeast two hybrid interaction test. Experiments were performed for kaposin B, DR2 and DR1 
repeat regions, Grb2 full length (Grb2) and the c-terminal SH3 domain of Grb2 (Grb2 C-SH3) as 
described in Material and Methods. Since kaposin B and DR1 activated reporter gene expression if 
expressed from the bait vector pGBKT7 (containing the GAL4 DNA-binding domain) interactions with 
these proteins could be assayed by expressing them from the prey vector (containing the GAL4 
activation domain) only (n.d.: not done). The interaction between DR2 and DR1 shown by luciferase 
reporter gene assay, IF and Co-IP could not be detected in this experiment.  
pGBKT7
--++Grb2 C-SH3
-(+)+++Grb2
false
positiven.d.n.d.DR1
--n.d.DR2
---control
DR1DR2kaposin B
pGADT7
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Fig. 27: The SH3 adaptor protein Grb2 interacts with kaposin B  
Co-immunoprecipitation of kaposin B and full length Grb2. The antibodies used for the 
immunoprecipitation are indicated below the gels, antibodies used for detection by Western blot up on 
the right side of the gels and the constructs transfected above the gels. Kaposin B and Grb2 were 
expressed in 293 cells using pGBKT7 and pGADT7 plasmids, in which they are expressed under T7 
promoter control. Specific bands are indicated by arrows. 
 
 
In yeast two hybrid-experiments kaposin B (but not the single repeat regions) was 
found to interact with full length Grb2 as well as with the c-terminal SH3 domain. 
Interaction tests with kaposin B and the DR1 repeat region were tested by expressing 
them from the prey vector only, since both constructs showed reporter gene 
activation if fused to the Gal4 DNA-binding domain (Table 2). 
For co-immunoprecipitation, kaposin B and Grb2 were co-expressed in 293 cells 
under the control of a T7 promoter using vaccinia virus expressing T7 RNA 
polymerase as described in Materials and Methods. Proteins could be co-precipitated 
from both sides with either anti-DR1 mabs or an anti-grb2 polyclonal antibody. Bands 
at approximately 27 kd (for Grb2) and 48 kd (for kaposin B) were detected in the cell 
lysates of cells transfected or co-transfected with Grb2 and kaposin B but not in 
controls (Fig. 27 left panel and right panel, respectively). 
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5 Discussion 
 
Kaposi’s Sarcoma Associated Herpesvirus (KSHV), which is the representative of 2- 
herpesviruses in man, encodes the complex genomic kaposin locus consisting of two 
distinct sets of direct DR2 and DR1 repeats, followed by a short domain originally 
identified as open reading frame K12. By initiation at multiple alternative CUG (and 
GUG) and one single AUG start codons, a gradient of kaposin molecules with varying 
length and targeting motifs is expressed from one single transcript. In this study the 
expression pattern and the regulatory function of the kaposin locus was investigated 
in detail. The multitude of translational products from all three reading frames could 
be resolved and assigned to specific cellular compartments. Depending on the start 
codon used, DR1 repeats representing a functional effector domain are either fused 
to DR2 repeats containing a nuclear localization sequence, or to K12, which encodes 
a transmembrane domain. Nuclear expression of kaposin leads to an activation of 
the AP-1 transcription factor and cellular promoters. The data presented in this study 
indicate a novel autoregulatory mechanism based on bidirectional targeting of a viral 
protein to distinct subcellular compartments by expression from different start codons 
and reading frames. Moreover, it could be shown that certain isoforms have a mutual 
influence on each other. 
 
 
5.1 Expression pattern and cellular localization of kaposin isoforms 
 
In this work expression pattern and cellular localization of kaposin protein isoforms 
were examined by fractionation and immunofluorescence experiments. According to 
the results presented here and by others, kaposin A (K12) localized predominantly in 
tubulovesicular structures and in the detergent unsoluble membrane fraction 
(Muralidhar et al., 1998; Muralidhar et al., 2000; Kliche et al., 2001). Other 
investigators have been in doubt whether the K12 ORF is expressed at all, since 
internal initiation from the K12 ATG codon and extended ribosomal scanning (see 
below) of the 2.3 kb sized K12 transcript would be necessary (Sadler et al., 1999). In 
Fig. 10 (right panel), mAb 4F11 directed against the K12 ORF recognizes a band at 6 
kd corresponding to the predicted 60-amino acid product of K12 ORF, demonstrating 
that, in fact, kaposin A is expressed in BCBL-1 cells in vivo. In contrast to the 
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membrane association of kaposin A, kaposin B, which is the predominant BCBL-1 
K12 protein product, was found almost exclusively in the nucleus. The NLS 
responsible for this nuclear localization, was restricted to the DR2 repeats, which are 
very hydrophilic and harbor multiple basic amino acids, as it is known for other NLS. 
Since kaposin C fuses the DR2/DR1 repeat region and the hydrophobic C-terminal 
K12 ORF, this isoform was found to be membrane associated as hypothesized by 
Sadler and colleagues (Sadler et al., 1999). Furthermore, two additional groups of 
gene products could be separated. These isoforms initiate from multiple alternative 
CUG start codons within the DR1 repeats in frame 1 (representing  DR1-K12 ORF 
fusion proteins) or in frame 2 and 3 (consisting of DR1 only). For better 
discrimination, the terms kaposin D (DR1-K12 ORF) and kaposin E (DR1) were 
proposed for these polypeptides. According to their structure, these two isoforms 
localize in different cellular compartments. As shown in Fig. 12 and Fig. 15, kaposin 
D localizes in the unsoluble membrane fraction, wheras kaposin E is exclusively 
found in the cytosol. The difference in size between the two arrays of kaposin D and 
kaposin E corresponds to the 6 kd size of the K12 ORF.  
 
 
5.2 Kaposin expression and leaky scanning 
 
The present work presents strong evidence that KSHV expresses this variety of 
different kaposin isoforms by multiple translational initiation sites rather than 
differential splicing. Multiple translational initiation sites occur in two different 
situations, either reinitiation or leaky scanning. Both are mediated through complex 
mRNA secondary structures which have previously been shown to occur in a variety 
of different cellular and viral transcripts (Bos et al., 1981; Cao and Geballe, 1995; 
Chen et al., 2001; Jang et al., 1988). In KSHV, the latent v-FLIP, v-cyc and LANA-1 
genes are expressed from a polycistronic mRNA containing an IRES (Dittmer et al., 
1998; Low et al., 2001; Sarid et al., 1999). Currently it is thought that the number of 
genes expressed by reinitiation and leaky scanning is limited to two or three due to a 
strongly decreasing efficiency (Kozak, 2002). In case of kaposin, a multiplicity of 
proteins depending on the varying number of DR1 repeats is expressed in tumors 
and PEL cell lines. Kaposin thus represents the first case in which multiple initiation 
sites generate an array of 15 and more different protein isoforms.  
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Reinitiation occurs at polycistronic mRNAs which contain more than one, usually 
non-overlapping ORFs (Kozak, 2002). One or more short upstream ORFs are 
followed by a major, longer downstream ORF. The upstream ORF(s) have regulatory 
function as they reduce translational initiation at the major ORF.  
Leaky scanning is a mechanism that allows initation to occur at an upstream non-
AUG codon in addition to the first AUG of a transcript. It is hypothesized that GC-rich 
mRNA sequences form secondary structures which retard scanning and thus allow 
mismatched Met-tRNAi to bind to the upstream non-AUG start codon (Kozak, 1991). 
The kaposin mRNA reveals a similar structure, since CUG start codons precede a 
downstream AUG. Interestingly, the downstream AUG and the upstream CUG start 
codons are used during different phases of infection. Scanning appears to be 
maximally leaky during the latent phase, when only the latent kaposin A is expressed 
through a downstream AUG start codon, and minimally leaky during the lytic phase, 
when kaposin B, C, D and E isoforms are expressed from upstream CUGs (Fig. 28).  
 
 
Fig. 28: Ribosomal scanning is maximally leaky during the latent phase and minimally leaky 
during the lytic phase  
Schematic diagram of the kaposin protein isoforms expressed from different CUG and AUG start 
codons on the viral transcript (also compare Fig. 11). The model hypothesizes a translational initiation 
gradient from downstream to upstream start codons during the course of infection. Black and red 
triangles below the mRNA show the hypothesized start codon usage during latent and lytic phase. 
                                                                                                                   Discussion      
 
 75
This gives rise to the hypothesis that a gradient of translational initiation from 
downstream to upstream DR1 CUGs occurs during the course of infection. During 
the early lytic phase, downstream DR1 CUGs (near the K12 AUG which is used 
during the latent phase) generate short kaposin D and E isoforms which are less 
active. During the late lytic phase, upstream DR1 CUGs generate long kaposin D and 
E isoforms (as well as kaposin B and C) which are functionally more active in the 
presence of kaposin B.  
Leaky scanning is a well-known phenomenon in cellular and viral transcripts and can 
generate long and short protein isoforms which are targeted to different cellular 
compartments (Kwiatkowski et al., 1988; Oda et al., 1990; Holbrook and Danpure, 
2002). KSHV has adopted this cellular mechanism, however considerably refined. In 
KSHV, a coactivator domain is targeted to three different compartments, nucleus 
(kaposin B), cytosol (kaposin E) and vesicular or plasma membrane (kaposin C and 
D). The identical peptide sequence in all three reading frames allows KSHV to 
express a constant ratio of kaposin D and E independently of whether upstream or 
downstream CUGs are used (Fig. 28). Leaky scanning might be a regulated process 
with other cellular or viral proteins involved. In S. cerevisiae, translational reinitiation 
of cellular transcripts at the GCN4 locus is known to be regulated by eIF-2, which is 
phosphorylated and inactivated under starvation (Hinnebusch, 1993). A cellular 
regulator which (i) changes its expression level during the course of infection or (ii) is 
present at different levels in B lymphocytes and endothelial cells might be involved in 
the regulation of the kaposin isoforms. Alternatively, a viral factor could bind and 
stabilize the secondary structure of the mRNA sequence responsible for leaky 
scanning.  
It was previously shown that leaky scanning is caused by highly structured GC-rich 
mRNA leader sequences (Kozak, 1991). The DR2 and DR1 repeat regions comply 
well with this prerequisite due to their complex repeat character and high GC content. 
In fact, there is experimental evidence that RNA secondary structure might be 
involved in initation at downstream CUGs since it was not possible to express 
kaposin D without an artificial AUG upstream of DR1. However, good expression of 
kaposin D and E was observed if DR2 was present 5’ of DR1. Hence, DR2 appears 
to facilitate translation initiation at CUGs within DR1, probably due to a complex 
mRNA secondary structure. In line with this suggested function, the presence of DR2 
is highly conserved in all KSHV subtypes, even in a recently reported PEL tumor that 
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is not expressing kaposin B due to the lack of a CUG start codon 5’ of DR2 (Li et al., 
2002).  
 
 
5.3 Kaposin B mediated AP-1 induction is dependent on nuclear localization of 
the repeats 
 
Although multiple functions are known for kaposin A, so far no functional data have 
been reported for other kaposin isoforms (Kliche et al., 2001; Muralidhar et al., 1998). 
This study shows that kaposin B induces the transcription factor AP-1. This activation 
depends on a nuclear localization of DR2 and DR1 repeats, as kaposin D and E 
isoforms which are found in the cytoplasma failed to activate AP-1. Since nuclear 
translocation of DR1 by adding a SV-40 NLS was not sufficient to restore activation, 
DR2 not simply targets DR1 to the site of action, but also acts as a coactivator (Fig. 
23). AP-1 activation might play a role in cytokine induction, which is known to play an 
important role in the pathogenesis of KSHV. Recently, it was shown that AP-1 is 
induced by LANA-1 and upregulates IL-6 (An et al., 2002). In the present study, a 
slight upregulation of the IL-6 as well as the VEGF promoter was also observed, 
suggesting that kaposin might be involved in cytokine regulation (Fig. 16). However, 
due to its complex regulation kaposin might have other functions in parallel, similar to 
LANA-1, which is involved in tethering the genome to the host chromosome, viral 
replication, as well as in transcriptionally modulating viral and cellular genes. 
Currently the molecular mechanism how nuclear DR2 and DR1 repeats activate AP-1 
is not known.  
 
 
5.4 Interaction partners of kaposin 
 
Both DR2 and DR1 are proline-rich and contain two PxxP-motifs each (Fig. 29). 
Since PxxP motifs are known targets for proteins containing SH3 domains, there are 
several interaction partners possible for both domains. In this work, pull-down 
experiments and subsequent Western blot analysis showed indeed several SH3 
proteins as interaction targets of kaposin. Taken in account that kaposin isoforms 
consist of several DR2 and DR1 repeats, the high affinity to SH3 domains is not 
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surprising and it remains open if the interactions are more general than specific to a 
particular SH3 domain protein. SH3 domains are known to regulate protein 
localization, enzymatic activity and often participate in the assembly of 
multicomponent signaling complexes (Schlessinger, 1994; Mayer and Eck, 1995). 
Thus, interaction of one or more kaposin isoforms with these proteins support the 
hypothesis that kaposins are powerful regulatory molecules. Additionally to the PxxP-
motifs, DR2 contains a putative WW domain, which is also known to bind proline-rich 
peptides (Fig. 29). It might be possible that the interaction between DR2 and DR1 is 
based on a WW domain structure, although DR2 does not contain the WW 
consensus binding motif PPxY and PPLP. It is also possible that DR2 
intramolecularly interact with DR1, but currently there is no evidence for this. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 29: Amino acid sequence of the DR2 and DR1 repeat 
DR2 peptide sequence (top); DR1 peptide sequence (below). PxxP-motifs and proline-rich stretch are 
green underlayed. Tryptophans of the putative WW domain are blue underlayed and connected. 
 
 
5.5 Differential targeting modulates functional activity 
 
Epstein Barr Virus (EBV), the next KSHV homologue in man, belongs to the 1-
subfamily of herpesviruses. It uses a different strategy to generate distinct protein 
isoforms. The latent EBNA-1, 2 and 3 protein isoforms are generated by differential 
splicing. Similar to KSHV, however, EBV generates different isoforms of regulatory 
proteins to modulate it’s function: the N-terminally abridged LMP-2B is known to 
regulate the signalling activity of LMP-2A. In KSHV, five different kaposin isoforms 
TWCPPPREPGALLPGNLVPSSPGTWC
HPRNPARRTPGTRRGAPQEPGAADR2 
DR1 
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are necessary to control and modulate each other as shown in this study. The DR1 
coactivator domain is either expressed with a NLS in the nucleus, a transmembrane 
domain in vesicular cellular organelles and the plasma membrane, or as a single 
domain in the cytoplasma (Fig. 30). Hence a model is proposed in which there might 
be an equilibrium of kaposin E in different compartments, which is modulated by 
other kaposin isoforms. This modulation is either towards activation (kaposin E is 
targeted into the nucleus by kaposin B) or deactivation (kaposin E is targeted to 
vesicular and plasma membranes by kaposin C and D). 
 
 
 
Fig. 30: Co-expression and differential targeting modulates the functional activity of different 
kaposin isoforms 
Schematic diagram depicting the model by which cytosolic kaposin E is bidirectionally targeted either 
into the nucleus by kaposin B or to vesicular and plasma membranes by kaposin C and D.  
 
 
5.6 Significance and implications 
 
In principle, KSHV gains additional coding potential by using all three reading frames 
of the kaposin locus. However, genomic space limitation is unlikely to be the primary 
evolutionary selective force for expression of a particular gene in herpesviruses 
which have large genome sizes between 110 and 230 kb. The present study 
suggests that the complex expression regulation is necessary to generate a 
meticulous stoichiometric distribution of kaposin isoforms, which appears to be of 
critical importance for the virus. Since CUG start codons are present with an identical 
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sequence context in all three reading frames in DR1, kaposin D and E are expressed 
at a ratio of 1:2 independently of whether upstream or downstream DR1 CUGs are 
used (Fig. 6). More evidence for the importance of the ratio between the different 
kaposin isoforms comes from the observation that the number of the repeats varies 
markedly between KS tumors, but the number of DR2 and DR1 repeats is always 
maintained at a ratio of approximately 1:2 (Russo et al., 1996; Sadler et al., 1999). 
Additionally, the maintenance of this ratio may also be crucial for the proper folding or 
structure of the proteins. Due to the stringent regulation, kaposin probably plays an 
important role in virus pathogenicity. The complex genomic structure of kaposin 
allows the virus to titrate or fine-tune a specific viral function, probably an essential 
factor in the pathogenicity. During the course of infection or in a cell-type specific 
fashion, kaposin might generate a gradient of effector molecules leading to a 
continous switch of a specific function. In conclusion, this work presents evidence 
that 2-herpesviruses developed a completely different strategy, leaky scanning, in 
comparison to 1-herpesviruses, which predominantly use differential splicing, to 
control viral replication and cellular processes. 
 
 
5.7 Perspectives 
 
Future experiments may reveal additional functions of kaposin isoforms. Due to the 
various proline-rich binding motifs in both repeats, many interactors are possible, and 
the suggested switch function therefore may induce several signaling events. The 
prediction of those additional functions may be possible by the determination of new 
interactors. This question can be addressed by performing yeast two hybrid screens 
with kaposin domains. Additionally, experiments examining the kinetics of kaposin 
expression have to be carried out to investigate the proposed switch model in detail. 
Functional analysis is tightly linked to structural definition of kaposins and more 
structural data are necessary to confirm predictions of sequence analyses. A 
prerequisite for this is the purification of kaposin domains and isoforms, which 
enables the performance of spectroscopic and structural analysis. The conservation 
of the repeat regions and the complex translational program through practically all 
KSHV subtypes already strongly suggests that kaposin isoforms have important 
functions in the viral life cycle. 
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7 Abbreviations 
 
Å      Angström 
A, Ade     adenine 
AIDS      aquired immune deficiency syndrome 
AP-1      activator protein 1 
APS       ammonium persulfate 
ATCC      American Type Culture Collection 
ATP       adenosine triphosphate 
BCBL-1     body cavity-based lymphoma cell line 1 
BCIP       5-bromo-4-chloro-3-indolyl-1-phosphate 
bp       base pair 
°C      degree Celsius 
C      cytosine 
dUTPase Deoxyuridine 5'-triphosphate 
nucleotidohydrolase 
DMEM      Dulbecco’s modified Eagle medium 
DMF      N,N-dimethylformamide 
DMSO      dimethyl sulfoxide 
DNA       deoxyribonucleic acid 
DO      dropout 
DR      direct repeats 
dNTP       deoxynucleoside triphosphate 
DTT       dithiothreitol 
E. coli      Escherichia coli 
e.g.      exempli gratia (Lat. = for instance) 
et al.      et alii (Lat. = and others) 
EDTA      ethylenediamine tetraacetic acid 
eGFP      enhanced green fluorescent protein 
ELISA      enzyme-linked immunosorbent assay 
ER       endoplasmatic reticulum 
EtOH       ethanol 
FCS       fetal calf serum 
f.l.      full length 
Fig.       figure 
FITC       fluorescein isothiocyanate 
g       gram 
g       gravitation constant 
G      guanine 
Grb2      growth factor receptor-bound protein 2 
h       hour(s) 
HAc       acetic acid 
HCMV      human cytomegalovirus 
HEPES  2-[4-(2-Hydoxyethyl)-1-piperazinyl]-ethane 
sulfonic acid 
HHV-8 human herpesvirus-8 
His Histidine 
HIV       human immunodeficiency virus 
HSV       herpes simplex virus 
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IF      immunofluorescence 
IFN       interferon 
IgG       immunglobulin G 
IL      interleukin 
IP      immunoprecipitation 
IPTG       isopropylthiogalactoside 
ISRE       IFN-stimulated response element 
kb       kilo bases 
kbp      kilo base pairs 
kd       kilodaltons 
KS      Kaposi’s Sarcoma 
KSHV      Kaposi’s Sarcoma associated herpesvirus 
l       liter 
LANA      Latency-Associated Nuclear Antigen 
LB       Luria-Bertani 
Leu      leucine 
LTR      long terminal repeats 
µ       micro (10-6) 
m       milli (10-3) 
m       meter 
M       mol/liter, molar 
MCMV      murine cytomegalovirus 
mab      monoclonal antibody 
MCD      multicentric Castleman’s disease 
MCP      major capsid protein 
min       minute(s) 
MOPS      3- (N-Morpholino)propanesulfonic acid 
mRNA      messenger RNA 
n       nano (10-9) 
NB      NaCl/bicine 
NBT       nitro blue tetrazolium 
NFB       nuclear factor kB 
NLS      nuclear localization signal 
o/n       overnight 
OD       optical density 
ORF       open reading frame 
p       pico (10-12) 
PAGE      polyacrylamide gel electrophoresis 
PBS       phoshate buffered saline 
PCR       polymerase chain reaction 
PEG      polyethylene glycol 
PEL      primari effusion lymphoma 
PMSF      phenylmethylsulfonfluoride 
prec.      precipitation 
RNA       ribonucleic acid 
rpm       revolutions per minute 
RPMI      Rosswell Park Memorial Institute 
RT       room temperature 
s       second(s) 
SBEG      sorbitol/bicine/ethylene glicol 
SD      synthetic defined 
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SDS       sodium dodecylsulfate 
SIV       simian immunodeficiency virus 
SV-40      Simian virus 40 
Tab.       Table 
TAE      Tris-Acetate-EDTA 
TBST      Tris buffered saline with Tween 20 
TEMED      N, N, N’, N’-tetramethylenediamine 
T      thymine 
TPA      12-O-tetradecanoylphorbol-13-acetate 
Tris       Tris(hydroxymethyl)aminomethan 
Trp      Tryptophane 
U       unit(s), enzyme activity 
untr      untransfected 
UV       ultraviolet 
V       Volt 
VZV       varicella zoster virus 
v/v       volumen/volumen 
WB      Western blot 
w/v       weight/volumen 
wt       wild type 
WW domain  domain that contains 2 conserved 
tryptophans and binds proline rich proteins 
SH3 domain Src homology 3 domain 
X--Gal 5-Bromo-4-chloro-3-indolyl--D-
galactopyranoside 
YPD yeast extract/peptone/dextrose 
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